Identification and care of patients at risk of post-stroke dementia by Tang, Eugene Yee Hing
 
 
Identification and Care of Patients 
at Risk of Post-Stroke Dementia 
 
Thesis submitted for the degree of 









Eugene Yee Hing Tang 
Population Health Sciences Institute 
Newcastle University 







Stroke can directly cause cognitive difficulties but also increases the risk of future 
dementia. There is often less focus on these consequences during standard care, 
which tends to concentrate on physical function. The seven publications described in 
this thesis focussed on four aims, which were to: a) describe the impact of cognitive 
difficulties post-stroke over time b) understand patient and professional views 
regarding current care for stroke-survivors with memory problems c) describe the 
acceptability and accuracy of dementia risk prediction models following stroke d) 
understand healthcare professional views about how to meet the cognitive needs of 
stroke-survivors. A mixed-methods approach was used to address these aims 
including: a) A systematic review of studies found there was a tendency towards 
cognitive decline, but this was not consistent as patients post-stroke can stabilise or 
even recover; b) Semi-structured interviews with i) stroke-survivors reporting memory 
difficulties and their family carers and ii) primary and secondary care professionals 
consistently reported clear gaps in care for stroke survivors with memory deficits; c) 
Harmonisation of international stroke cohorts to externally validate existing dementia 
risk prediction models which have not validated well in stroke populations. Further, in 
the qualitative interviews, patients, family carers and healthcare professionals 
identified challenges to their implementation; d) A national electronic-Delphi survey 
found that stroke clinicians believe assessment of post-stroke cognition needs better 
integration into services with clarification of when and where this should be done to 
streamline access. The gaps in current services mean that the support available to 
care for and identify those at greatest risk for dementia is lacking. Patients and carers 
should be offered information about the long-term cognitive consequences post-
stroke. If required, they should be encouraged to seek assistance in the community 
with the aim of being directly referred back into specialist services for assessment 
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Chapter 1: Why is post-stroke dementia a problem? 
1.1 Background and Rationale 
Cerebrovascular disease is a common cause of dementia in old age with stroke 
being the second most common cause of acquired cognitive impairment and 
dementia (O'Brien et al., 2003). Although dementia is frequent after stroke, and can 
include different dementia subtypes e.g. vascular dementia and Alzheimer’s disease 
(Desmond et al., 2000), not all stroke-survivors who develop cognitive problems meet 
the criteria for dementia (Sun et al., 2014). Cognitive impairment following a stroke is 
associated with institutionalisation, disability and increased mortality (Leys et al., 
2005b). Further, cognitive impairment post-stroke also leads to poorer quality of life 
(Ankolekar et al., 2014). For some, cognitive impairment may progress to a dementia 
illness. With an ageing population and a decline in mortality after stroke (Rothwell et 
al., 2004), the rates of post-stroke dementia will increase particularly since the 
incidence of stroke (Rothwell et al., 2005) and dementia (Fratiglioni et al., 2000) both 
rise exponentially with age. Despite this, cognitive impairment, which may be as 
common as other neurological (motor and sensory) deficits, is an often-overlooked 
and neglected consequence post-stroke (Jacova et al., 2012).  
The levels of early cognitive impairment post-stroke is concerning with over 
half of stroke-survivors found to have cognitive impairment after 6 months in one 
study (Mellon et al., 2015). Looking beyond 6 months, in the UK, long-term cognitive 
impairment exists even in 22% and 21% of patients at 5 and 14 years respectively 
post-stroke (Douiri et al., 2013). Pooled dementia rates in hospitalised stroke 
survivors indicate that 10% have dementia within the first year after their first-ever 
stroke (Pendlebury and Rothwell, 2009, Pendlebury, 2012). This increases to over 
30% in those with recurrent stroke (Pendlebury, 2012, Pendlebury and Rothwell, 
2009). However, it is not clear what happens to stroke survivors beyond this early 
post-stroke period. Stroke-survivors’ cognition may remain stable, improve over time 
or progress to dementia following their stroke (Rasquin et al., 2005, Ballard et al., 
2003). Aetiologically, it is likely that factors including large and small vessel disease 
as well as neurodegenerative pathology combine to determine the pattern of 
cognitive deficit in the post-stroke individual (Kalaria et al., 2016). Indeed, cognitive 
deficit is prevalent in the majority stroke survivors even with successful clinical 




Stroke care has been identified as a clinical priority by the NHS Long Term 
Plan, with one of the aims to improve post-hospital rehabilitation (National Health 
Service, 2019). The Intercollegiate Stroke Working Party has produced expert 
consensus guidance for clinical services (Intercollegiate Stroke Working Party, 2016). 
In the 5th edition, a recommendation (2.12.1F) for stroke services is that it should 
“include clinical neuropsychology/clinical psychology provision for severe or 
persistent symptoms of emotional disturbance, mood or cognition.” including routine 
follow-up after hospital discharge and annually thereafter (Intercollegiate Stroke 
Working Party, 2016). By providing these reviews, it is hoped that stroke-survivors 
can feel supported in the long-term and provide access to other specialist services, 
even though these are not well defined. This had led to the implementation of the six 
month reviews for stroke survivors by the Commissioning for Quality and Innovation 
(CQUIN) (NHS England, 2019). It is clear however that stroke survivors continue to 
feel unsupported. A survey by the Stroke Association found that 77% of stroke 
survivors have problems with their memory and nearly 50% said that the support they 
received for memory  and fatigue problems was poor (Stroke Association, 2016). 
Research into cognition is important to stroke-survivors, caregivers and health 
professionals (Pollock et al., 2014). In contrast, physical recovery is well researched 
with evidence showing improvements following organised rehabilitation with personal 
goal setting (Van Peppen et al., 2004). 
Given that a proportion of individuals may go onto develop dementia, earlier 
identification of those at-risk particularly for a future dementia illness could be one 
way to ensure patients are provided with the support, services and interventions they 
need to continue to live well in the community. One approach in clinical services, 
which has also been well researched in dementia, is the concept of risk assessment 
or prediction. Numerous models have actually been developed to predict an 
individual’s risk of future dementia for the general population (Hou et al., 2019, 
Stephan et al., 2010, Tang et al., 2015). There has been one model developed for 
stroke patients (Lin et al., 2003). However, none are currently being used clinically 
due to a lack of assessment in terms of transportability, generalisability and also 
acceptability to patients and health professionals.   
1.2 Problems Identified 
 Despite the frequency of post-stroke cognitive impairment and dementia, it is 





expressing dissatisfaction with current clinical services. Although acute stroke is 
managed in secondary care, primary care will inevitably take over the management 
of these individuals. However, there is no national consensus around the role of each 
team in the care of stroke-survivors with cognitive difficulties. If risk prediction models 
were to be used in the context of stroke, then we need to assess whether existing 
models are sufficient for stroke-survivors to predict dementia or whether further 
development work is needed. It is also important to consider where these models sit 
in the clinical care pathway. 
 
1.3 Thesis Overview 
1.3.1 Research question(s): 
 
Are current clinical services able to identify and support stroke-survivors at risk of 
post-stroke cognitive difficulties and dementia? 
 
1.3.2 Aims and Objectives 
The aim of this programme of work was to critically review the care received 
by people who have had a stroke and are therefore at increased risk of dementia. 
Several broad aims were set in the hope of answering this through the different 
phases of work planned: 
i) To describe the impact of cognitive difficulties post-stroke over time 
ii) To describe the current care provision from the perspectives of patients, 
carers and key professionals 
iii) To explore the use of risk prediction tools to identify those most at risk and 
iv) To seek the views of professionals on the key findings from objectives (i) 
and (ii) with a view to suggesting improvements in future care. 
1.3.3 Supporting Chapters and Papers 
To support this thesis, there are seven published papers. 





Chapter Two is a literature review around the epidemiology and scale of the problem 
and presents the reasons for better care of this stroke population and challenges that 
healthcare services currently face. 
Chapter Three synthesises the available data, in the form of a systematic review, 
around the longitudinal trajectory of cognitive test scores in stroke over time. This 
chapter includes: PP1: (Tang et al., 2018a).  
Chapter Four presents qualitative research conducted with stroke-survivors and their 
family carers with particular emphasis on the impact on their daily lives. This chapter 
includes PP2: (Tang et al., 2020a) - invited to participate in the “Dementia in Primary 
Care” collection. 
Chapter Five presents qualitative research on the views of patients, their family 
carers and healthcare professionals on the current care pathway for post-stroke 
memory difficulties. This chapter includes PP3: (Tang et al., 2017a) and PP4: (Tang 
et al., 2018c) 
Chapter Six presents both qualitative and quantitative assessments on the suitability 
of risk prediction models for dementia in stroke as a means to identify those at the 
greatest risk of post-stroke dementia earlier. This chapter includes PP5: (Tang et al., 
2020b) and PP6: (Tang et al., 2019) 
Chapter Seven provides evidence of expert consensus with regards to how best to 
manage post-stroke cognitive problems within the stroke service. This chapter 
includes PP7: (Tang et al., 2020c) 
Chapter Eight is a summary discussion on the following: principal findings of the 
thesis, strengths and limitations of the studies, how the findings of this study relate to 









Chapter 2: Current opportunities to ensure early detection of post-
stroke dementia 
2.1 The burden of stroke  
Stroke itself is a leading global cause of both mortality and disability with high 
economic burden due to both treatment of the disease as well as post-stroke care 
(Rajsic et al., 2019). Although globally there have been substantial reductions in 
mortality rates from stroke, the overall burden of stroke remains high due to 
population ageing leading to an expanding proportion of older individuals (GBD 2015 
Neurological Disorders Collaborator Group, 2017). In 2016, it was estimated that 
there were more than 80 million stroke survivors (GBD 2016 Stroke Collaborators, 
2019). Greater numbers of stroke-survivors will also equate to higher numbers of 
individuals living with chronic stroke and its effects and also higher demands on post-
stroke care. 
According to a report in 2018 by the Stroke Association there are more than 
100,000 strokes in the UK each year, which is around one stroke every 5 minutes 
(Stroke Association, 2018c). It is important to note that around 1 in 4 individuals will 
experience another stroke within 5 years (Stroke Association, 2018c). In community 
based samples, around 1 in 5 middle-aged women and 1 in 6 middle aged men will 
have a stroke in their lifetime (Seshadri and Wolf, 2007). Between 2015 and 2035, it 
has been projected that the incidence of stroke in the UK will increase by 60% per 
year and prevalence to increase by 120% (King et al., 2020). The aggregate annual 
costs of stroke care are estimated to be around £26 billion with unpaid care 
accounting for £15.8 billion (61% overall) and NHS care £3.4 billion (13%) (Patel et 
al., 2019). Although unpaid care reduces pressure and costs on formal services, we 
need to be mindful of the pressure this places on carers’ and their own need for 
support to manage this responsibility (Patel et al., 2019). This has been projected to 
rise to £43 billion in 2025 and £75 billion in 2035 which represents an increase of 
194% over 20 years (King et al., 2020). 
To help with this, there is national guidance published by National Institute for 
Health and Care Excellence (NICE), which recommended that stroke-survivor’s 
health and social care needs and the needs of their carers are reviewed at six 




Excellence, 2013). This in theory is there to assist in the overall rehabilitation of the 
individual in terms of both physical, emotional and cognitive recovery. 
2.2 Post-stroke cognitive deficits and dementia    
Both stroke and dementia are defined as age-related diseases i.e. they are 
diseases with increasing incidence rates among the adult population (Chang et al., 
2019). They are also related in that stroke is known to be a strong and independent 
risk factor for all cause dementia (Kuzma et al., 2018). Indeed, a previous systematic 
review and meta-analysis found that ten per cent of individuals developed dementia 
soon after their first stroke with more than a third suffering from dementia after 
recurrent stroke (Pendlebury and Rothwell, 2009). Further, the incidence of dementia 
a year after a major stroke is nearly 50 times higher than that in the general 
population (Pendlebury and Rothwell, 2019). It is also estimated that a stroke illness 
could accelerate the onset of dementia by 10 years (De Ronchi et al., 2007). 
Symptomatic stroke could therefore play a more prominent causal role rather than 
due to just the underlying vascular risk factors associated with both diseases.  
2.3 Epidemiology of Post-Stroke Dementia 
 A number of different factors determine the overall prevalence of PSD 
including study setting (e.g. hospital vs. population-based studies), stroke type and 
severity and whether the individual has had recurrent stroke. A previous systematic 
review found that the prevalence of PSD ranged from 7% (population-based sample 
with pre-stoke dementia cases excluded) to 40% (hospital-based patients with 
recurrent stroke and pre-stroke dementia cases not excluded) (Pendlebury and 
Rothwell, 2009). A more recent meta-analysis looked at the prevalence of post-stroke 
neurocognitive disorders (NCD), and reported that major post-stroke NCD prevalence 
was 16.5% (95% CI: 12.1 – 20.8) (Barbay et al., 2018a). However, when mild and 
major NCD was defined according to other criteria (e.g. VASCOG criteria (Vascular 
Behavioural and Cognitive Disorders)), the prevalence of major NCD fell to 10.4% 
(95% CI 7.4 – 134) (Barbay et al., 2018b). However, it is clear from these studies that 
there needs to be a harmonised definition of post-stroke dementia (PSD) so that 
accurate cross-study comparisons can be made.  
2.4 Defining Post-Stroke Dementia 
Dementia is a syndrome that affects an individual’s cognitive abilities and 
behaviour, and subsequently interferes with a person’s ability to perform activities of 





predictable loss of cognitive function, trajectories for deterioration may vary according 
to individual factors, underlying mechanisms and domains being assessed. The 
concept of vascular dementia (VaD) has traditionally been based on the multi-infarct 
model and ischaemic vascular disease (Hachinski et al., 1974). More recently, other 
criteria have been proposed for dementia in the context of vascular disease including 
1) the National Institute of Neurological Disorders and Stroke – Association 
Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS-
AIREN) (Roman et al., 1993); 2) State of California Alzheimer's Disease Diagnostic 
and Treatment Centers (ADDTC) (Chui et al., 1992); and, 3) The Diagnostic and 
Statistical Manual of Mental Disorders 4th Edition (DSM-IV) (American Psychiatric 
Association, 1994). Unfortunately, these criteria fail to allow for milder impairments 
outside of dementia. Further, memory is a pre-determining requirement to diagnose 
dementia in both NINDS-AIREN (Roman et al., 1993) and DSM-IV criteria (American 
Psychiatric Association, 1994). This is problematic as VaD patients tend to have 
superior function in verbal long term memory compared with AD patients (Looi and 
Sachdev, 1999). A broader term, namely vascular cognitive impairment (VCI) was 
introduced, which included all forms of cognitive impairment, from mild to severe, 
where the underlying cause is assumed to be due to cerebrovascular disease 
(O'Brien et al., 2003). Vascular dementia therefore sits on a continuum, which 
includes vascular cognitive impairment without dementia, vascular mild cognitive 
impairment and also dementia (O'Brien et al., 2003). VCI therefore encompasses 
those with cognitive impairments associated with a diverse cerebrovascular 
pathologies including lacunae, small-vessel disease with white matter lesions, 
multiple cortical and subcortical infracts and stroke (O'Brien et al., 2003). Specifically, 
at the time O’Brien and colleagues described PSD to include cases with multiple 
corticosubcortical infarcts, strategic infarcts, subcortical ischaemic vascular dementia 
and AD (O'Brien et al., 2003).  
Regarding PSD, there are numerous definitions. Henon and colleagues (Leys 
et al., 2005a, Henon et al., 2006) definition of PSD includes all types of dementias 
that occur after stroke irrespective of their cause. Mijajlovic and colleagues, based on 
the proceedings of the International Congress on Vascular Dementia (2015), defined 
PSD as any form of dementia which develops following a clinical cerebrovascular 
event (Mijajlovic et al., 2017). By defining PSD in this way there is no assumption 






a mix of both vascular insults and neurodegeneration (Brainin et al., 2015, Mijajlovic 
et al., 2017). In the context of dementia, defining PSD can be challenging. One of the 
differentiating factors between cognitive impairment and dementia is usually based 
on limitations to activities of daily living (Sachdev et al., 2015). In the context of 
stroke, post-stroke physical sequelae may themselves lead to physical impairments 
without it being secondary to cognitive dysfunction. Further, as stroke and dementia 
tend to occur in older adults, one confounding factor may be that the stroke-survivor 
already had pre-existing diagnosed or undiagnosed cognitive impairment (Mijajlovic 
et al., 2017). It has also been suggested that the diagnosis of PSD should be delayed 
by at least 6 months after the event (Mijajlovic et al., 2017) as acute deficiencies in 
cognitive test scores may well improve when retesting in the short term (Wagle et al., 
2010).  
Other more recent definitions of PSD have a temporal relationship to stroke. 
For example, The Vascular Impairment of Cognition Classification Consensus study 
(VICCCS) defined PSD as a patient who exhibits immediate and/or delayed cognitive 
decline within 6 months of the stroke that does not reverse (Skrobot et al., 2017). 
Within this definition PSD is a subtype of the broader category of major VCI whereas 
VaD represents a severe form in the continuum of VCI. PSD is further 
subcategorised if a comorbid neuropathology is present, namely Alzheimer’s Disease 
(AD), Dementia with Lewy Bodies (DLB) or other contributions (Skrobot et al., 2017).  
A further set of criteria for vascular cognitive disorders was produced from the 
Congress of the International Society for Vascular Behavioural and Cognitive 
Disorders conferences in 2009 and 2013 (Sachdev et al., 2014). Vascular cognitive 
disorder is present if there is the presence of a cognitive disorder and vascular 
disease is determined to be the dominant if not exclusive underlying causative 
pathology for the cognitive disorder. Cognitive disorder is further divided into mild and 
major cognitive disorders, with major cognitive disorder being equivalent to dementia 
(Sachdev et al., 2014).  
This thesis uses the definition proposed by Mijajlovic and colleagues, i.e. any 
form of dementia which develops following a clinical cerebrovascular event (Mijajlovic 




2.5 Screening and Case Finding for Dementia  
Population screening looks to test asymptomatic individuals for a disease in 
order to increase earlier detection and therefore treatment of a disease (Maxim et al., 
2014). However, at present, there is insufficient evidence to assess the benefits and 
harms in screening for cognitive impairment in asymptomatic individuals over the age 
of 65 years (Moyer, 2014). At present, the United Kingdom (UK) National Screening 
Committee (NSC) does not recommend universal screening for dementia (The UK 
National Screening Committee, 2019). The main reason being that there is no 
evidence of either accurate screening tests for dementia in those who have not 
already presented with symptoms nor are there effective treatments (The UK 
National Screening Committee, 2019). Screening for dementia raises complex issues 
for the public and clinicians and a systematic review of the literature has found that 
population screening for dementia may not be acceptable to either group (Martin et 
al., 2015b).  In some cases, screening may identify individuals with symptoms but for 
various reasons have yet to present to a healthcare professional. Perceived lack of 
benefit, taboos surrounding dementia and the associated costs (including perceived 
financial motivations to implement screening) have been documented as barriers for 
patients and the public when it comes to population screening for dementia (Martin et 
al., 2015a). On the contrary, there is evidence that the greater the level of worry and 
concern about getting dementia can mean that they are more willing  to be screened 
or tested for dementia (Tang et al., 2017b). 
 At present patients suspected of having a diagnosis of dementia, either 
because they or their caregiver are concerned about their memory or cognition, 
would present to their General Practitioner (GP) to undergo cognitive screening 
(Mate et al., 2017). The most recent NICE guideline recommended shorter cognitive 
tests such as the 10-point cognitive screener or the 6-item cognitive impairment test 
over tests such as the MMSE or the MoCA (Pink et al., 2018). Another approach is 
known as “case finding” i.e. offering investigation to identify the possible signs and 
symptoms of a dementia illness where the patient is at high risk of the disease and it 
may be of benefit to the patient (Ranson et al., 2018). It has been found that a case-
finding approach could detect most people with dementia and presents the best 
opportunity for timely recognition of dementia in the community (Mate et al., 2017). 
This case finding approach consisted of either the clinical judgement of the GP or 




cognition concern and their disclosure or intent to disclose to their GP (Mate et al., 
2017). In the UK, active case finding has been implemented previously in the 
community, seeking to opportunistically identify at-risk patients based on for example 
vascular risk factors, Parkinson’s disease and learning disabilities (National Health 
Service (England), 2015). A similar hospital based approach (the National Dementia 
CQUIN) was also implemented to case find amongst those aged over 75 who were 
admitted as an emergency to either hospital or community services without a 
previous diagnosis of dementia (National Health Service (England), 2014). In the 
United States, the Medicare Annual Wellness Visit has also been used to detect any 
cognitive impairment if the individual shows signs or symptoms of cognitive 
impairment or if there are concerns raised by family members, friends, caregivers 
and others (Cordell et al., 2013). However, it can be argued that due to the subtle 
differences between case finding and screening, case finding is simply screening 
without an evidence base to protect the public against false positives or negatives 
(Cordell et al., 2013). In the context of stroke, stroke-survivors would certainly have 
met the criteria for the previous primary care enhanced service as older stroke-
survivors would be classed as “at-risk” (National Health Service (England), 2015), but 
this service was dropped in 2016  as it was felt that GPs were more routinely 
diagnosing dementia (https://www.england.nhs.uk/2016/02/gp-contract-16-17/). 
Indeed, based on current gaps in evidence, there are recommendations against 
dementia case-finding in clinical practice (Ranson et al., 2018).  
2.6 Screening for Post-Stroke Cognitive Decline 
Cognitive impairment following a stroke is common (Jaillard et al., 2009) and is 
strongly associated with quality of life following a stroke (Cumming et al., 2014). A 
recent meta-analysis found that 40% of patients display some degree of cognitive 
impairment (no dementia) in the first year following a stroke (Sexton et al., 2019). 
There is currently no gold standard cognitive assessment in the context of stroke. A 
recent systematic review looked at various cognitive screening tools to differentiate 
vascular cognitive impairment and VaD from controls. In terms of screening tools, 
they found that the Montreal Cognitive Assessment (MoCA) test could reliably and 
accurately distinguish between controls and both VaD and Vascular Mild Cognitive 
Impairment (VMCI) (Ghafar et al., 2019). A number of cognitive screening tools are 
currently in use (see table 1). In a study, when screening tools were compared, there 




displayed high sensitivity with a short assessment time (Lees et al., 2014). It should 
be noted however that many post-stroke cognitive deficits for example aphasia or 
visual problems are not so readily picked up by routine cognitive tests. Further, time 
of day also seems to affect cognitive performance when MoCA was used in older 
adults in the context of TIA and stroke (Mazzucco et al., 2017). A short cognitive 
screen, the Oxford Cognitive Screen (OCS), has been developed specifically for 
stroke patients which can be completed in 15-20 minutes and takes into account 
post-stroke domain specific impairments such as aphasia and neglect (Demeyere et 
al., 2015). When the OCS was compared against the Mini Mental State Examination 
(MMSE), the OCS found a much higher incidence of cognitive deficits post-stroke 
with the discrepancy particularly strong for those with milder strokes (Mancuso et al., 
2018). Further, the OCS was found to detect high incidences of cognitive 
impairments specific to stroke which were not detected by the more traditional MMSE 
(Mancuso et al., 2018). The OCS also translates well across other e.g. Chinese and 
Russian populations (Hong et al., 2018, Shendyapina et al., 2019, Valera-Gran et al., 
2019).  
Table 1. Comparison of Different Cognitive Tests 
Cognitive Test 
Score 






(Folstein et al., 
1975) 
• 6 cognitive domains tested 
(visuospatial, language, 
concentration, working 
memory, memory recall, 
orientation) (Cameron et 
al., 2013) 





(Nasreddine et al., 
2005) 





memory, memory recall 
and orientation) (Cameron 
et al., 2013) 









et al., 2015) 
• 10 tasks, five cognitive 
domains (attention and 
executive function, 
language, memory, 
number processing and 
praxis).  
• Brief evaluation of visual 
field defects 






for Stroke Patients 
(CASP) (Barnay et 
al., 2014) 
• Nine items evaluating 6 
cognitive functions 
(language, praxis, short-
term memory, temporal 
orientation, spatial/visuo-
construction neglect and 
executive functions) 











2.7 Benefits of Earlier Identification of Cognitive Failure and Dementia 
  The World Alzheimer Report (2011) has previously highlighted the importance 
of an early dementia diagnosis (Pollock et al., 2012). To further qualify this, it has 
been proposed that the diagnosis of dementia should be “timely” (De Lepeleire et al., 
2008), responding to concerns raised by the older person and their family rather than 
screening for early signs or symptoms of dementia (Prince et al., 2011). Timeliness is 
not dictated by when in terms of chronological time but rather the “right” or opportune 
time (Dhedhi et al., 2014). Despite the implementation of national dementia plans 
with commitment to early detection and diagnosis (Gardner S. O. and Splaine 
Consulting., 2017), a European survey reported that, from the perspective of family 
carers, timely diagnosis of dementia is found in only about half of cases (Woods et 
al., 2019).  
 A previous systematic review identified nine studies looking at the benefits and 
challenges of a timely diagnosis of confirmed AD, however, none of these studies 
specifically looked at diagnosing prodromal AD (Dubois et al., 2016). Some of the 




and postponing institutionalisation (Dubois et al., 2016). For the patient timely 
diagnosis of AD could also reduce anxiety by addressing concerns about the 
individual’s early symptoms and subsequent earlier access to treatment (Dubois et 
al., 2016). For the family and caregivers, it can provide answers to their concerns and 
enables access to support and resources that could reduce caregiver strain (Dubois 
et al., 2016). Certainly, barriers to timely diagnosis include stigma (Gauthier et al., 
2013, Dubois et al., 2016) and whether it is appropriate to diagnose people in the 
initial symptomatic stages of the illness given the lack of effective treatments (Dubois 
et al., 2016). However, there seems to be more positivity around an earlier diagnosis 
of dementia. A recent study in Australia, reported that a significant majority (92%) of 
young and older adults preferred a diagnosis of dementia to be disclosed as soon as 
possible (Watson et al., 2018). Even though cultural differences may influence early 
detection of dementia (Lee et al., 2011), a separate cohort from Hong Kong also 
favoured wanting to know the diagnosis of dementia as soon as possible (Lam et al., 
2019).  
2.8 Risk Prediction Models Used to Assist in Earlier Diagnosis  
2.8.1. Risk Prediction Models Used in Medicine 
Understanding prognosis or risk in developing a disease is a common area in 
clinical research particularly as it may enable individuals to make lifestyle changes 
and plan ahead for their future personal circumstances. Indeed, whether or not an 
individual develops an illness or complications associated with the illness can depend 
on a number of different individual factors. This can be a mixture of demographic 
(e.g. age, education level and sex), social (e.g. smoking and alcohol history), health-
related (e.g. history of certain medical conditions), genetic or even radiological 
factors. Given the heterogeneity and variability amongst individuals, it would be 
unlikely that a single predicting variable would be able to provide an accurate level of 
prognosis or risk hence the need for “multivariable research” (Moons et al., 2009). 
There is therefore a desire to include biomarkers or disease-specific variables to 
improve the specificity and sensitivity of these models. 
Clinical risk prediction models, risk score or prognostic models typically use a 
variety of different patient specific variables in order to predict health outcomes over 
time (Moons et al., 2009, Pavlou et al., 2015). Common outcomes can be the 
development of a disease, death or complications. These models therefore enable 




will occur in this individual (Moons et al., 2009). These estimates can then be used to 
guide and inform individuals on not only the possible prognosis or development of the 
disease but also to assist with treatment decisions.  
There are numerous risk prediction models that have been developed for both 
research and clinical use. Examples include respiratory (e.g. outcome in chronic 
obstructive pulmonary disease (Bellou et al., 2019), childhood asthma (Smit et al., 
2015)), emergency medicine (Brink et al., 2019), cardiovascular (e.g. heart failure (Di 
Tanna et al., 2020, Sahle et al., 2017), atrial fibrillation outcomes (Deng et al., 2017)), 
obstetrics (e.g. to predict for preeclampsia (De Kat et al., 2019)) and cancer (e.g. 
prognostic outcomes for pancreatic cancer (Bradley et al., 2019), survival in prostate 
cancer (Thurtle et al., 2019), breast cancer (Louro et al., 2019), liver cancer 
recurrence after transplantation (Al-Ameri et al., 2020)), transplantation (e.g. survival 
after heart transplantation (Aleksova et al., 2019). There have also been 
comparisons between different methods of modelling e.g. logistic regression versus 
machine learning (Christodoulou et al., 2019).  
In terms of model performance, a model needs to be able to discriminate 
accurately between those who have the desired outcome and those without. The 
ability to stratify with sufficient probability can assist with clinical management 
decisions. Measures of discrimination include the concordance statistic and the area 
under the receiver operating characteristic curve (Steyerberg et al., 2010). A perfect 
model would therefore have an area of 1 (Steyerberg, 2009) with prognostic models 
typically between 0.6 and 0.85 (Royston et al., 2009). In general, a poorly 
discriminating model would probably have a c-statistic of 0.6 and a well 
discriminating model would have a c-statistic of 0.8. However, this should not be the 
only determining factor when choosing a risk prediction model (Steyerberg et al., 
2010). 
2.8.2. Commonly Used Clinical Risk Prediction Models  
In terms of clinical usage, these have generally been in cardiovascular and 
cerebrovascular disease. The most well-known model that is routinely used in clinical 
practice, particularly in primary care, are the QRISK models to predict 10-year 
cardiovascular disease risk. The first QRISK model was developed in 2007 
(Hippisley-Cox et al., 2007), with the updated QRISK2 published in 2008 and has 
been continually updated to reflect the changes in population characteristics 




cohorts (Collins and Altman, 2009, Arts et al., 2015, Pike et al., 2016, Collins and 
Altman, 2012) and QRISK2 is recommended in national guidance used across the 
NHS particularly with regards to lipid modification (Robson, 2008, National Institute 
for Health and Care Excellence, 2014, Health Improvement Scotland, 2017). In the 
field of cerebrovascular disease, models such as the ABCD2 score have been used 
to risk stratify individuals. ABCD2 uses variables such as age, blood pressure, clinical 
features of a transient ischaemic attack (TIA), duration of symptoms and a history of 
diabetes to determine who are at high risk of stroke following a TIA (Johnston et al., 
2007). This model had previously been included in national guidance for stroke 
management, which dictated in particular how soon the patient should receive 
specialist assessment (National Institute for Health and Care Excellence, 2008). In 
the original development and validation paper, the c-statistics score varied from 0.62 
– 0.83 (Johnston et al., 2007). In 2010, the ABCD2 was further improved by including 
the presence of ≥2 TIA symptoms within 7 days to the original score and termed 
ABCD3 (Merwick et al., 2010). Further improvement could be gained by including 
imaging variables such as carotid stenosis and abnormal acute diffusion-weighted 
imaging i.e. ABCD3-I (Merwick et al., 2010).  
This guidance has recently been updated to reflect up to date evidence which 
has found that risk prediction scores (such as ABCD2 and ABCD3) when used by 
themselves do not discriminate high and low risk individuals well enough for it to be 
used (National Institute for Health and Care Excellence, 2019).  Although the 
additional imaging variables do improve prediction, these are not readily found in 
primary care. However, there is evidence that the additional neuroimaging variables 
have been found to predict long term stroke risk after TIA (Kiyohara et al., 2014). 
Based on this evidence, it was felt that immediate specialist assessment would result 
in better health and economic outcomes for the entire TIA population without using 
this risk stratification tool (National Institute for Health and Care Excellence, 2019). 
This reversal in the use of a risk prediction tool in national guidance highlights the 
importance of thorough validation and testing prior to implementation particularly 
when you consider the original score’s relatively modest range of discrimination 
scores.    
2.8.3 Examples of Dementia Risk Prediction Scores 
 One of the most heavily researched risk models is the population based 




follow-up (Kivipelto et al., 2006). The first model consists of both modifiable and non-
modifiable variables (see table 2). The second model is model 1 with APOE ε4 
status. The AUC for model 1 was 0.77 (95% CI 0.71 – 0.83) and model 2 was 0.78 
(95% CI 0,72 – 0.84). The CAIDE score has been externally validated with similar 
levels of accuracy in midlife populations (36.1 years follow-up) (C statistic 0.75) 
(Exalto et al., 2014) but less accurate when shorter follow-up duration (10 years) was 
used (Licher et al., 2018b). A higher CAIDE score has also been associated with 
increased risk of cerebral infarcts (Hooshmand et al., 2018), related to MRI indicators 
of cerebrovascular changes and neurodegeneration (Stephen et al., 2017) including 
more severe white matter hyperintensities (Vuorinen et al., 2015). An App has also 
been developed using the CAIDE score to encourage users to actively reduce the 
risk factors which they are able to modify to potentially postpone the onset of 
cognitive impairment and dementia (Sindi et al., 2015). One of the most important 
uses of the CAIDE score to date has been its application in the Finnish Geriatric 
Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) trial 
(Ngandu et al., 2015). The FINGER trial aimed to use a multidomain intervention 
(diet, exercise, cognitive training, vascular risk monitoring) in those with a CAIDE 
score of at least 6 points and cognition at mean or slightly lower than that expected 
for age (Ngandu et al., 2015). This 2-year intervention trial found that this intervention 
could improve or maintain cognitive function in an at-risk elderly population (Ngandu 
et al., 2015). This methodology has now spread internationally (Rosenberg et al., 
2020). From the FINGER trial, there seems to be some benefits in both global 
cognition and domain-specific cognition with plans for a 7 year extended follow-up to 
assess whether the intervention had any effects on dementia and Alzheimer’s 
disease incidence (Ngandu et al., 2015). Within the context of stroke, the effect is 
unclear as only 5% of the intervention group reported a history of stroke and no 
stratified analyses was done (Ngandu et al., 2015).  
Some models have looked at using modifiable variables either on its own or in 
the majority of variables used in the model with a view to enable an individual to 
potentially modify and lower one’s risk for a dementia illness. This is because around 
a third of Alzheimer’s diseases cases worldwide may be attributable to potentially 
modifiable factors (Norton et al., 2014). The Australian National University AD Risk 
index (ANU-ADRI) is an example of a self-report risk index that was developed using 




model contains 11 risk factors and four protective factors (see table 2) (Anstey et al., 
2014). Three cohort studies were used in the validation of the model with a follow-up 
time ranging from 3.5 years to 6 years (Anstey et al., 2014).  When assessing 
predictive accuracy of the models the C-statistics ranged from 0.637 – 0.740; when 
common variables were used (age, sex, education, diabetes, smoking and alcohol), 
the C-statistics were 0.666 – 0.734 (Anstey et al., 2014). When the model was 
externally validated for 10-year dementia risk the C-statistics for risk prediction was 
0.75 but was similar to a model using age alone (C-statistic 0.77) (Licher et al., 
2018b).  
A similar approach was used for the Lifestyle for Brain Health (LIBRA) score 
(Deckers et al., 2015). This is a model developed from both systematic review of 
available literature and also Delphi consensus from experts (Deckers et al., 2015). 
The score consists of twelve modifiable risk factors and protective factors (see table 
2) (Deckers et al., 2015). The score has been validated in midlife populations, which 
found that higher LIBRA scores were associated with higher dementia risk up to 30 
years later (Deckers et al., 2020). However, when the model was tested in a large 
population dataset with 16 years follow-up, the AUC was only 0.60 (Schiepers et al., 
2018). When they added education to this model, the AUC was 0.59; when 
education, age and sex were added the AUC was 0.75 (Schiepers et al., 2018). The 
benefit of a model containing modifiable risk factors means that it might enable the 
at-risk individual to modify their overall risk by making the necessary lifestyle 
changes. However, the overall accuracy of these variables seems to be lower than 
those where non-modifiable variables have been used. It also highlights the 
importance of age in these dementia risk models as a significant predictor, given that 
age alone models can perform just as well as these other models (Licher et al., 
2018b). 
There have also been disease-specific models in particular for diabetes. The 
type 2 diabetes-specific dementia risk score (DSDRS) was one of the first models 
created for diabetics to predict dementia (Exalto et al., 2013). This model was found 
to be able to predict dementia in diabetics at 10 years using a mixture of non-
modifiable variables such as age and education alongside some diabetes specific 
variables (see table 2)  (Exalto et al., 2013). The C-statistic for the development 
cohort was 0.736 and 0.746 for the validation cohort (Exalto et al., 2013) and has 




developed to predict dementia for Chinese type 2 diabetic patients where the 
following variables were used: age, sex, duration of type 2 diabetes, body mass 
index, variation in fasting plasma glucose and HbA1c, stroke, hypoglycaemia, 
postural hypotension, coronary artery disease and ant-diabetes medication  (Li et al., 
2018). The model was able to accurately predict dementia in diabetic populations 
with the following follow-up duration and AUC’s: 3 years =0.82 (development), 0.84 
(validation), 5 years = 0.79 (development) 0.80 (validation), 10 years = 0.76 
(development), 0.75 (validation). A further model has been developed in those with 
diabetes and hypertension with good discriminatory accuracy (c-statistics 0.806 (95% 
CI 0.799 – 0.812) (Mehta et al., 2016). From these studies we can see that perhaps 
there are benefits when including variables that are disease-specific such as diabetic 
complications in the context of diabetics being at risk of dementia.  
Table 2. Comparison of Common Dementia Risk Models 
 Non-Modifiable Variables Modifiable Variables 
Cardiovascular Risk 
Factors, Aging and 





(APOE ε4 status) 
Systolic blood pressure 




University AD Risk index 
(Anstey et al., 2013, Anstey 





Traumatic brain injury 
Depressive symptoms 
Smoking 









Lifestyle for Brain Health 
(Deckers et al., 2015) 












Type 2 diabetes-specific 
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Brief Dementia Screening 





History of type 2 diabetes 
History of stroke 
Needs help from others to 
manage money or 
medications 
Antidepressant medications 
or reports that “everything 
was an effort” for 3 or more 
days per week over the past 
week. 
  
Some clinical risk prediction models have become routinely implemented for 
use in primary care for example cardiovascular risk prediction models to assist 
primary care clinicians when deciding on anti-cholesterol treatment (National Institute 
for Health and Care Excellence, 2014). Some dementia risk prediction models have 
been designed with primary care use in mind, for example by utilising data from 
primary care records. In a model using primary care routinely collected data (see 
table 2 for variables), it was found that in people aged 60-79 years this was model 
was able to accurately predict dementia at 5 years (C-statistic 0.84) but not for those 
aged over 80 years (Walters et al., 2016). A further model was developed and 
validated as a brief dementia screening indicator for primary care by Barnes and 
colleagues (Barnes et al., 2014). Four studies (the Cardiovascular Health Study, the 
Framingham Heart Study, the Health and retirement Study and the Sacramento Area 
Latino Study on Aging) were selected and predictive factors were chosen that were 
available in all or most of the cohorts and would be readily available or easily 
accessible in primary care (see final variables selected in table 2) (Barnes et al., 
2014). The C-statistics ranged from 0.68 – 0.78 but did only include those aged 
between 65 – 79 (Barnes et al., 2014).  
 Overall, there is great variation in the overall accuracy of these models. 
Although there have been moves towards trying to use mainly modifiable variables 
so that an individual can modify their risk, models containing non-modifiable variables 




2.9 The Challenges of Dementia Diagnosis in Primary Care 
 In the UK, GPs are the first point of contact for patients and their families who 
are concerned about their memory and/or cognitive abilities. GPs therefore have a 
key role in symptom recognition, investigation, initial cognitive screening and 
subsequent referral to specialist services to gain access to anti-dementia drugs 
(National Institute for Health and Care Excellence, 2018). However it is estimated 
worldwide that over 60% of dementia remains undiagnosed in the community and/or 
residential/nursing care, although the studies included in this systematic review were 
mainly from high-income countries (Lang et al., 2017). Factors associated with under 
detection may be to do with low socioeconomic levels for example in China (Chen et 
al., 2013), although this was not universally true as the same was not found in North 
America (Lang et al., 2017). In the UK, the undetected rate of dementia ranged from 
42% in the community (O'Connor et al., 1988) and 32% (Lithgow et al., 2012) to 53% 
(Collerton et al., 2009) in the setting of residential/nursing care or mixed community 
and residential settings. In the meta-analysis it was found that there was increased 
undetected dementia if the diagnosis was made by GPs (Lang et al., 2017). Lack of 
support, time and financial constraints and diagnostic uncertainty have been cited as 
barriers to dementia diagnosis in primary care (Koch and Iliffe, 2010). In the UK, to 
improve detection rates and management of dementia in primary care, educational 
interventions have been trialled with some mixed success (Downs et al., 2006, 
Wilcock et al., 2013) with educational interventions being used in other parts of the 
world also (Schutze et al., 2018). The study by Downs and colleagues tested three 
education interventions: an electronic tutorial, decision support software and practice 
based workshops (Downs et al., 2006). Significant improvement in reported rates of 
dementia cases was obtained in the decision support software written inside the 
existing electronic medical record software and practice-based workshop groups 
(Downs et al., 2006). The trial by Wilcock and colleagues only used tailored practice-
based workshops and did not improve dementia case identification (Wilcock et al., 
2013). Finally, Schutze et al utilised a mixture of education programmes including 
small and large workshops and online modules but have yet to determine the long-
term effects of their educational programme in terms of improving detection rates of 
dementia (Schutze et al., 2018). The intervention has found that participants could 
report improved knowledge, attitudes and practices and was found to be well 
received by its participants (Berenbaum et al., 2019). In the context of stroke, 




heighten awareness to improve detection for a dementia illness in this at-risk group 
particularly for primary care healthcare professionals. 
2.10 Chapter Summary 
 PSD is common but there is variation in how it is defined. There are 
challenges in how we screen and identify those who are at risk. These individuals 
may benefit from earlier intervention although the concept of a “timely” diagnosis of 
any dementia illness needs to take into account patient preferences. Upon discharge 
from stroke services, patients may face challenges when seeking a dementia 
diagnosis in the community. It is important to clarify to clinicians what the cognitive 
trajectory is following stroke so that they know when such individuals may present 




















Chapter 3: Cognitive Trajectory Post-Stroke 
This chapter presents findings from a systematic review of studies looking at how 
cognition changes over time following a stroke. Studies of stroke patients (≥50 years 
old) including two or more cognitive assessments over time were pooled together. By 
looking specifically at cognitive assessments, we can also look at the trends of how 
stroke affects different cognitive domains. This first publication explores the trends of 
cognitive scores over time and also looked at what variables could be associated 
with any subsequent cognitive impairment. This is particularly important for the 
subsequent studies looking at risk assessment for stroke-survivors for a future 
dementia illness.    
3.1 What happens to cognition following a stroke? 
There have been systematic reviews which examined all-cause dementia or 
study defined incident dementia as an outcome longitudinally (Kuzma et al., 2018, 
Savva and Stephan, 2010). One previous systematic review found that a history of 
stroke roughly doubles the risk of incident all-cause dementia in those aged >65 
years (Savva and Stephan, 2010). This risk was independent of demographic and 
cardiovascular risk factors with more recent stroke leading to a greater association 
(Savva and Stephan, 2010). A more recent meta-analysis found that stroke was a 
strong risk factor for AD (risk ratio (RR) = 1.59, 95% Confidence Interval: 1.25 – 
2.02). Finally, a meta-analysis was conducted for the relationship between stroke and 
all-cause dementia risk (Kuzma et al., 2018). Here, across eight studies, the pooled 
estimate found that incident stroke more than doubled the risk of all-cause dementia 
(RR = 2.18, 95% CI 1.90-2.50) (Kuzma et al., 2018). Similarly the pooled hazard ratio 
for prevalent stroke for all-cause dementia was 1.69 (95% CI: 1.49 – 1.92) (Kuzma et 
al., 2018). These studies focussed on dementia as an outcome. However, it is 
important to look at long-term trajectories of test scores that also include cognitive 
deficits either globally or within specific domains. It may well be that over time some 
cognitive domains stabilise or indeed recover, or some cognitive domains are more 
readily affected in the immediate post-stroke setting. Further, the factors associated 
with decline, stability or recovery will be important to determine particularly if they are 
modifiable variables to reduce overall risk.  
3.2 PP1. Longitudinal Effect of Stroke on Cognition: A Systematic Review 
Tang EYH, Amiesimaka O, Harrison S, Green E, Price C, Robinson L, Siervo M, 

































































































































































































































































































































































































































































































































3.2.1 PP1 Commentary 
 In this systematic review (Tang et al., 2018a) we found that although the risk 
of cognitive decline is increased, cognitive outcome over time is variable.  The 
majority of the studies reported cognitive deterioration over time but there was also 
cognitive stability and cognitive improvement. However, it is important to note that 
factors such as follow-up time and the cognitive domain/test being assessed was a 
factor as to what the cognitive outcome would be over time. These changes in 
cognitive trajectory are not unexpected as the linear rate of cognitive change seen in 
the normal aging population is not always seen in the context of stroke (Mijajlovic et 
al., 2017). This may in part be due to varying degrees of baseline cognition pre-
stroke and changes to the rate of decline due to further insult (Mijajlovic et al., 2017). 
Intact cognition is vital to maintain independence and to be able to carry out activities 
of daily living. Identifying patterns of cognitive deficit and expected trajectory 
becomes important not just in the post-stroke rehabilitation phase but also post-
stroke recovery.  
 When looking at global cognitive function, significant decline was found in 
those who were followed-up over a longer period. Certainly when compared to non-
stroke controls, incident stroke has been found to lead to both acute cognitive decline 
but then also persistent cognitive decline over six years (Levine et al., 2015a). When 
stroke-survivors are followed-up for even longer, 30% of survivors screen positively 
for cognitive impairment at 15 years (Crichton et al., 2016). Cognitive batteries 
looking at global cognition will be important to determine whether individuals should 
be assessed further for a dementia illness. However, stroke patients will also develop 
cognitive impairment with deficits in specific cognitive domains without it leading to 
clinical dementia. In fact in the first year post-stroke 4 in 10 patients will develop 
cognitive impairment that does not meet the criteria for dementia but may require 
intervention (Sexton et al., 2019). These specific domains could be targeted by 
specific clinical groups e.g. speech and language therapy for language impairments 
or occupational therapists for issues with neglect. Similar to global cognitive function, 
the effects of stroke longitudinally on specific domains were mixed. There were 
improvements in some domains such as memory (delayed) (Wagle et al., 2010)  at 
shorter follow-up times, but then decline in others (Comijs et al., 2009, Reitz et al., 
2006) when there was longer follow-up, but not universally so. Findings in other 




information processing and language, were also generally mixed (Tang et al., 
2018a). From the point of view of the patient, subjective cognitive complaints are 
common following a stroke and they tend to increase over time (van Rijsbergen et al., 
2014). However, in some studies it has been found that objective cognitive 
performance does not always independently predict cognitive complaint  (Duits et al., 
2008) but memory difficulty is among the most frequently reported complaints (Lamb 
et al., 2013). When assessing the association between these subjective cognitive 
complaints and objective cognitive performances, the highest correlation was found 
on the memory domain (van Rijsbergen et al., 2014). A recent study also found that 
the association between objective cognitive performance and self-reported cognitive 
complaints 3 months post-stroke was found when a global assessment of objective 
cognitive performance was done (van Rijsbergen et al., 2017). Again, the strongest 
domain-specific associations between objective cognitive performance and 
subjective cognitive complaints was found when ecological tests in the memory 
domain are used (van Rijsbergen et al., 2017).  
Although objective cognitive decline may not always equate to poorer 
functional performance, it is important to be able to screen for these impairments as 
cognitive impairment is both prevalent post-stroke even with successful clinical 
recovery and also related to poor functional outcome (Jokinen et al., 2015). Memory 
complaints in particular are frequently reported by stroke patients. A recent large 
survey by the Stroke Association found that 83% of stroke patients have problems 
with their memory (Stroke Association, 2018a). There is some evidence that memory 
rehabilitation in stroke patients can help subjective memory problems in the short 
term but not significantly so in the long term (das Nair et al., 2016). Again this was 
not evident on objective memory testing (das Nair et al., 2016). A more recent 
systematic review however did find that psychological interventions may be effective 
to improve overall post-stroke cognitive function with memory and attention found to 
have greater benefit than other cognitive domains although the evidence was of poor 
quality and high risk of bias (Merriman et al., 2019). 
The choice of screening tools may be an important reason for this variability as 
well as other heterogeneities in design across studies. The studies in this systematic 
review used traditional cognitive test batteries such as the MMSE. However, stroke-
specific screening tools were missing in our review. Stroke specific cognitive 





Assessment Scale for Stroke Patients (CASP) (Barnay et al., 2014) have yet to be 
assessed in any longitudinal studies. This is despite the fact that when compared to 
the MMSE and MoCA, the CASP has been found to more feasible that the MMSE 
and MoCA in aphasic stroke patients as it takes into account patients with severe 
expressive aphasia by using visual items (Benaim et al., 2015, Barnay et al., 2014). 
Further, the OCS is able to detect a higher incidence of cognitive impairment in 
stroke patients when compared with the MMSE (Mancuso et al., 2018). When the 
OCS was compared to the MoCA, the OCS was able to detect significant numbers of 
patients with cognitive deficits (e.g. neglect, apraxia, number processing) that were 
undetected when using the MoCA (Demeyere et al., 2016). A substantial number of 
studies continue to report longitudinal cognitive outcomes but uniformity in, and 
standardisation of reporting outcomes are needed (Saa et al., 2019). Further, subtle 
deficits or changes in cognition may therefore not be detected using these other 
batteries and future studies should look to see if stroke-specific tools are able to 
assess the true nature of longitudinal cognitive trajectory. These tools will also allow 
for greater inclusion as they tend to enable the inclusion of those with aphasia and 
neglect. Universal inclusion should not be at the expense at reduced accuracy 
however and so care must be taken when comparing those with and without these 
deficits.  
 Finally, we also assessed factors that may be related to cognitive decline over 
time. This included demographic factors, such as age and sex, as well as 
depression, poorer baseline cognitive test scores and stroke-specific factors such as 
stroke location (Tang et al., 2018a), which are well known. Other studies have also 
found associations for progressive cognitive decline in those with other co-morbidities 
(coronary artery disease (Mahon et al., 2017), arrhythmia (including atrial fibrillation 
(Mahon et al., 2017, Tang et al., 2006), diabetes (Liman et al., 2011, Jacquin et al., 
2014, Wang et al., 2018), leg paralysis (Arba et al., 2017)) and social status (not in a 
relationship and unemployed (Mahon et al., 2017)). The ever-increasing numbers of 
risk variables makes it hard to know where interventions should focus on to reduce 
incident cognitive impairment and dementia. A better way to quantify this risk may be 
to use a risk assessment approach. Combining risk factors known to increase risk 
could allow clinicians to target specific populations of post-stroke individuals either for 





3.3 Chapter Summary 
 Post-stroke cognitive outcomes can vary as demonstrated across the studies 
included in this systematic review. This will be down in part to study heterogeneity 
and the cognitive tests used. However, cognitive trajectory post-stroke does not 
seem to be a linear process as compared to the general population. Incident stroke 
may itself accelerate a pre-existing cognitive deficit to the point of a dementia illness 
or may lead to transient changes in cognition. Better tools and assessment methods 























Chapter 4: What is the impact of memory deficits on stroke-
survivors? 
This chapter presents findings from the qualitative interviews conducted with 
particular focus on how memory difficulties have affected stroke survivors. It is 
important to understand that although physical recovery may occur for some, we 
need to understand the impact of the cognitive issues that patients may also 
experience. Often, these invisible disabilities are hidden from clinicians and service 
providers. This may be because patients and their families struggle to identify the 
appropriate service to pursue and are therefore left feeling unsupported in the 
community. 
4.1 Quality of Life After Stroke 
 Globally, the lifetime risk of stroke from the age of 25 is around 25% for both 
men and women (Feigin et al., 2018). In 2016 there was an estimated 80 million 
stroke-survivors (GBD 2016 Stroke Collaborators, 2019). Stroke is therefore a 
leading cause for mortality and disability with substantial associated economic costs 
(Rajsic et al., 2019, GBD 2016 Stroke Collaborators, 2019). Returning home to 
familiar environments having had a stroke can be challenging. For many, once they 
are home, patients can experience a deep change in their lives and they can also 
feel that they were now also a burden on their families (Simeone et al., 2015). 
Particularly as almost half of stroke-survivors living in the community require a 
caregiver at home to help them with post-stroke sequelae (Mayo et al., 2002). 
Further, relationships with a partner and family can also be negatively affected 
(McKevitt et al., 2011). As much of the informal care tends to be provided by family 
and partners (Greenwood et al., 2008), this places a significant degree of burden on 
these individuals. Treatment burden, defined as the amount of work of healthcare for 
patients (Eton et al., 2012), is also significantly influenced by the configuration of both 
health and social care (Gallacher et al., 2018). Examples of treatment burden include 
the fact that patients need to make sense of stroke and planning care, needing to 
interact with others e.g. their family doctor, family members and allied health 
professionals and being able to carry out management strategies (Gallacher et al., 
2018). So, we can see that not only does the stroke-survivor need to be able to 
manage any post-stroke sequelae, but they also have to learn to adjust to new 




Rachpukdee and colleagues have also found that a predictor of unsatisfactory 
quality of life was severe cognitive impairment (Rachpukdee et al., 2013). Even 
following a TIA or minor stroke, patients and healthcare professionals recognise the 
impact of cognitive impairment (Turner et al., 2019). At the more severe end of the 
spectrum, dementia following a stroke can remain undetected. In the community, it 
has been estimated that over 60% of cases of dementia were undetected (Lang et 
al., 2017). Amongst a number of factors, low priority to discuss cognitive impairment 
with a physician, assuming that these changes are part of normal aging as well as 
fears around dementia all contribute to a missed or delayed diagnosis of dementia 
from the patient’s perspective (Bradford et al., 2009). This means that it would be 
extremely difficult for primary care clinicians to be able to pick up those that need the 
additional support, intervention and onward referral to memory clinic services to 
obtain a diagnosis of dementia. It is therefore important for clinicians to be aware of 
how cognitive changes such as memory problems are affecting stroke survivors on a 
day to day basis to help them recognise those that require additional attention.  
4.2 PP2.  Impact of Memory Problems Post-Stroke on Patients and their Family 
carers 
Tang EYH, Price C, Stephan BCM, Robinson L, Exley C. (Frontiers in Medicine); 


























































4.2.1 PP2 Commentary 
 In this paper, themes relating to the impact of stroke and also subsequent 
memory problems on the patient and their family were analysed. Participants in this 
study provided examples of difficulties in their daily lives and also the emotional 
impact of these difficulties. However, they also discussed ways that they would adapt 
to their new difficulties. These compensatory strategies could mean that they would 
either delay or even avoid seeing a healthcare professional. This would also mean 
these deficits remain invisible to healthcare professionals whilst the stroke-survivor 
and family carers continue to struggle on in the community.  
 Longer term outcomes can remain poor for stroke-survivors with stroke often 
seen as another step towards declining health (Hawkins et al., 2017). There also 
tends to be much emphasis on physical recovery and rehabilitation following a 
stroke. Patients themselves will focus on the physical issues when discussing overall 
recovery even  if they reported symptoms related to cognition problems such as 
memory loss deficits which have a negative impact on their lives (Ellis et al., 2013). 
Specifically cognitive difficulties following a stroke can affect a stroke survivor’s 
recovery (Babulal et al., 2015) and in particular post-stroke physical functioning 
(Nyunt et al., 2014). In a study looking at domain specific problems encountered by 
stroke-survivors, nearly all participants reported cognitive changes with no 
differences across gender or ethnicity (Pappadis et al., 2019). In this study, nearly 
half of participants reported memory difficulties with examples provided including 
difficulty in remaining focussed or walking away whilst cooking (Pappadis et al., 
2019). Emotional problems following a stroke are known to be a common occurrence 
(Chen et al., 2019a) which also tends to be less frequently met when compared to 
other problems such as problems with incontinence, mobility, speaking, reading sight 
and falls (McKevitt et al., 2011). The emotional impact expressed by participants was 
within the context of their changing roles due to either lack of confidence or loss of 
independence.   
This study was able to provide more an in-depth account of not only the effect 
of these memory difficulties but how participants were compensating for these 
difficulties. In a qualitative meta-synthesis of literature focused on the experience of 
those living with stroke, similar themes were found although did not look specifically 
at those living with cognitive changes (Salter et al., 2008). In this synthesis of 




representing the stroke-survivor’s resilience and ability to make changes to focus on 
more positive aspects of their lives (Salter et al., 2008). Similarly, a further study 
looking at the process of adjustment over time post-stroke found that part of this 
process was termed “evolving a new normal” (Theadom et al., 2019). Over time, 
participants in this study were not only more aware of their limitations but were able 
to make adjustments to their life (Theadom et al., 2019), similar to participants in my 
own study. Adaptations may be perceived as a negative consequence post-stroke. 
This is because the need to adapt has meant that the individual has needed to 
perhaps adjust away from their former selves to live with their new post-stroke selves 
and subsequent disabilities. A systematic review of qualitative studies found that in 
order for stroke-survivors to adapt and recover, the individual also needs to engage 
in this process. Engagement in meaningful activities can help the stroke-survivor 
attain a sense of belonging, purpose and to regain some of the autonomy they may 
have lost and includes social participation (Lou et al., 2017). This was certainly 
relevant to one participant in the qualitative study who spoke of purposely doing 
some learning before meeting up with his social circle so that he could continue to 
engage with them and remain relevant to his peers (Tang et al., 2020a). Many of 
these adaptations are often made without the explicit assistance of healthcare 
professionals. Healthcare professionals themselves may not be aware of the 
additional “work” that the patient has had to give themselves in order to adapt, 
engage and recover.  
4.3 Chapter Summary 
 Although previous qualitative studies have looked at the long-term trajectory of 
recovery post-stroke, this qualitative study has been able to track the trajectory of a 
specific subcategory of stroke patients i.e. those who are struggling with their 
memory. In general, the themes are similar to the ones the general stroke population 
may face. It is clear from these accounts that stroke-survivors with memory problems 
are able to learn to adjust to their new post-stroke selves. They are able to adapt and 
make seemingly small changes to continue to function in the community. However, 
there are undeniable physical and also importantly hidden emotional affects that this 
can have on the stroke-survivor and their family. Many stroke-survivors with memory 
problems feel that the support they receive for these problems is poor. It is not clear 
whether this is because the support available was substandard (or not available) or 




to be able to clarify the stroke survivors’ clinical journey from specialist assessment to 

























Chapter 5: Views of stakeholders on current care for post-stroke 
cognitive deficits? 
In this chapter, findings from a qualitative interview study with clinicians involved in 
post-stroke care are presented. This included both primary and secondary care 
clinicians. The views and experience of stroke-survivors and their family carers were 
also sought. These interviews were conducted to gain a more in depth understanding 
of the current clinical service pathway for stroke patients presenting with cognitive 
difficulties such as memory problems, in order to highlight any issues or gaps in care. 
The aim of this study was to assist in the development of other approaches to assist 
clinicians in future service improvements and/or identify questions for future research.  
5.1 Clinical Care of Memory Problems Post-Stroke 
 The potential problems a stroke-survivor may face in the recovery and 
rehabilitation phase are extensive. Cognitive deficits, such as overall cognitive 
impairment, difficulties with memory, attention and concentration, executive function 
and spatial awareness, can all impact on the patient (Rodgers and Price, 2017). The 
multidisciplinary nature of stroke care ensures that deficits such as these can be 
addressed via appropriate professional expertise from a range of staff via post-stroke 
clinical contact with the patient and their families. Memory deficits post-stroke are 
common even when there has been successful functional recovery (Jokinen et al., 
2015). National clinical guidance has recommended therapy to preserve abilities as 
well as being trained in compensatory techniques e.g. electronic reminders or written 
checklists (Intercollegiate Stroke Working Party, 2016). This is particularly relevant as 
specific cognitive domains such as attention and memory have been found to show 
greater benefit from psychological interventions than other domains (Merriman et al., 
2019).  There have been repeated calls for clinicians to take a more active role in the 
area of post-stroke cognition (Lodder, 2007, Pantoni, 2017). At present much post-
stroke care and research focuses on physical recovery with cognitive issues often not 
always addressed. As stroke survival increases in an aging population, the bulk of 
stroke care may further overwhelm the chronic post-stroke phase. This is particularly 
important as the biggest increase in stroke care costs is anticipated to be in social 
care (King et al., 2020). This has led to international consensus recommendations 
culminating in the Berlin Manifesto which calls for the joint prevention of stroke and 




As an initial step to understand the clinical aspects of this growing problem, it 
was firstly important to clarify from the clinician’s perspective the pathway for 
managing stroke-survivors with subsequent memory deficits as to whether there may 
be gaps in care for stroke-survivors with subsequent memory deficits. 
5.2 PP3. Gaps in care for patients with memory deficits after stroke: views of 
healthcare providers 
Tang EYH, Price C, Stephan B, Robinson L, Exley C. (BMC Health Services 

















































































































































































































































5.2.1 PP3 Commentary 
In this study, barriers and facilitators were identified from clinicians when 
describing their ability to provide ongoing care to stroke-survivors with memory 
deficits. In term of barriers, four themes were identified: 1) Less focus on memory 
and cognition in post-stroke care; 2) Difficulties in bringing up cognition and memory 
problems post-stroke; 3) Lack of clarity in current services; 4) Assumptions made by 
healthcare professionals introducing gaps in care (Tang et al., 2017a).  
Deficiencies in clinical post-stroke care are not a new finding. In this study 
participants brought up both lack of clarity and gaps in care. Stroke is often seen and 
prioritised as an emergency condition which has resulted in well integrated systems 
to provide acute stroke care. However, the challenge has been to be establish and 
integrate care pathways beyond emergency and acute stroke care. (Baeza et al., 
2012). There is often variability in post-hospital care and stronger links between 
stroke-specific clinicians, community specialists and GP are needed as highlighted 
by the participants in this study. This is important as the overall cost of stroke care 
(including informal care and lost productivity due to stroke) is around £9 billion a year 
(Saka et al., 2009). However, as the annual direct cost of stroke in the UK is around 
£4 billion, it is clear that the post-stroke care in the community is the most costly. For 
example, community care and informal care costs account for 32% (around £2.9 
billion) and 27% (around £2.4 billion) of the overall cost respectively (Saka et al., 
2009). A more recent costs analysis of stroke care has found that health care costs 
are expected to rise to £43 billion in 2025 and then £75 billion in 2035 with social 
care costs projected to rise more rapidly than unpaid care, and health care costs in 
the next 20 years (King et al., 2020).There is therefore a need to better understand 
care in the post-acute phase and to provide cost-effective interventions and care 
which is better suited towards individual needs. Given the frequency of cognitive 
deficits shortly post-stroke (Lo et al., 2019), including memory problems, earlier 
identification could result in earlier intervention, signposting and support which may 
help to reduce the costs of informal care or even costs attributed to lost productivity 
due to disability. Early intervention could be initiated in hospital settings and then 
followed-up in the community. Unfortunately, the latest annual SSNAP report has 
found that although there has been increase in the percentage of patients receiving 
mood and cognition screening before leaving hospital (from 78% (2013/14) to 93% 




input when they need it is only 10% (Sentinel Stroke National Audit Programme, 
2020). This highlights the lack of inpatient psychological services for stroke patients 
and is not something that has improved significantly over the years given that in 
between 2013/14 to 2018/19, there has only been a 4% increase in the percentage of 
days in which psychology input is received for those that require it (Sentinel Stroke 
National Audit Programme, 2020). This then means that the majority of patients 
requiring input for their cognitive difficulties are then needed to be picked up either at 
their subsequent stroke reviews or when they are in the community. However, the 
barriers identified by the clinicians involved in their care mean that this is likely to be 
difficult.  
The participants also highlighted some potential facilitators in the care of 
stroke-survivors with cognitive/memory difficulties. These included 1) stronger links 
between primary and secondary care; 2) information provision at all stages of care.  
Stronger links are needed between hospital and community settings as the patient 
will eventually transfer from one clinical setting to another. This transfer, however, 
does not equate to full cognitive recovery and so unless these links are in place, 
there is a risk, as evidenced by the themes identified in this study, that individuals 
with memory difficulties are lost to clinical services and left to manage themselves. 
Even up to five years after stroke, cognitive and memory difficulties are common and 
form part of unmet clinical and social needs (McKevitt et al., 2011). At present, given 
that patients are discharged from specialist services, there needs to be greater 
community and primary care-based strategies and involvement to plug these gaps in 
care. A survey of stroke-survivors confirmed that over half do want more information 
particularly about their stroke (McKevitt et al., 2011). A study looking at the online 
forum of the Stroke Association (Talkstroke) found that the main reason for forum 
participation was to request or offer information and support in over half or 
participants (De Simoni et al., 2016). In terms of forum topics, the lack of 
understanding of the invisible effects of stroke, which includes memory and cognitive 
problems, was found to be the topic generating the highest numbers of posts and 
users (De Simoni et al., 2016). A single six-month review is unlikely to facilitate much 
in the way of information provision (and retention for the recipients of this information) 
in the long-term. Given that information provision can have positive effects on patient 




presented to stroke-survivors and their family throughout their stroke recovery, which 
does not end upon discharge from six-month stroke review.  
5.3 Supporting Stroke-Survivors beyond Specialist Settings 
Long-term post-stroke care recommendations, as informed by the National 
Stroke strategy, included the fact that all stroke survivors should have a six-month 
review (Department of Health, 2007a) with national clinical guidance recommending 
routine follow up (Intercollegiate Stroke Working Party, 2016). In general, stroke-
survivors should be offered a six-month review of their stroke followed by annual 
reviews by the GP with the aim of picking up any persisting physical, emotional or 
cognitive deficits. These reviews allow patients to access clinical services for these 
deficits with the aim of ensuring they are supported in the community.  
Previous research from a randomised control trial where the intervention was 
a structured re-assessment system for patients and carers at 6 months post-stroke 
versus existing care looked at patient independence and carer stress as outcomes 
but did not find any clinically significant evidence of benefit at 12 months (Forster et 
al., 2009). However, the long-term disabilities post-stroke i.e. beyond 12 months, 
have been highlighted with over a third of stroke-survivors remaining disabled 5 
years post-stroke (Luengo-Fernandez et al., 2013). Although a proportion of these 
may end up being institutionalised, many will also be living in their own homes and 
therefore continue to require long term support and to be identified as needing 
support. In the long-term, GPs and community practitioners will therefore be 
managing patients and their families who are living with or assisting those with 
potentially significant physical, emotional and cognitive difficulties. The six-month 
review could therefore be used as an initial point of identification of those who are in 
need and then highlighted to primary care. Primary care therefore provides a central 
role to coordinate care from the point of specialist service discharge (Hare et al., 
2006) and care beyond 6 months may be required to see clinically significant 
problems that need to be addressed. It may also be that regular reviews beyond a 
one off 6-month review in specialist settings can lead to behaviour change, ongoing 
review and subsequent intervention. This would then sit within the community with 
GPs and the primary care team. However, a survey of GPs found that only a third of 
respondents were aware of the need for regular reviews for stroke-survivors 
(Goncalves-Bradley et al., 2015). Only around half of all stroke-survivors were 




identified 75% of GPs surveyed did not have an established protocol to address this 
(Goncalves-Bradley et al., 2015). The survey did find that around 80% of the reviews 
that were occurring, this included memory and general cognition (Goncalves-Bradley 
et al., 2015) suggesting that perhaps GPs themselves understood the importance of 
post-stroke cognitive care.  
In 2018, the Stroke Association conducted their largest ever survey of stroke 
survivors and carers. In general nearly one in four stroke survivors felt that the follow-
up care they received post-hospital discharge did not help them to cope (Stroke 
Association, 2018b). Specifically 1 in 5 of those surveyed felt that they needed more 
frequent or longer access to their GP or practice nurse (Stroke Association, 2018b). 
The survey found that on average people reported six different problems with their 
cognition with 83% of participants reporting a memory problem without much 
improvement in this area (Stroke Association, 2018a). Further help to deal with 
problems with memory was rated poorly in this survey (Stroke Association, 2018b). 
For patients and carers, research into cognition is amongst the top ten priorities with 
regards to life after stroke (Pollock et al., 2014). Therefore, it is important to identify 
what barriers patients with memory difficulties post-stroke and their family may face 
when trying to access help upon discharge from specialist services.  
5.4 PP4. Post-Stroke Memory Deficits and Barriers to Seeking Help: Views of 
Patients and Carers. 









































5.4.1 PP4 Commentary 
From a patient perspective, unmet needs post-stroke appears to be a common 
occurrence. A large survey with stroke-survivors had previously found that around 
40% had reported memory problems, with over half reporting that this need was 
unmet (McKevitt et al., 2011). In this study with patients and their family caregivers, 
gaps in care for those who develop post-stroke cognitive problems are described. 
Similar to our previous paper on the views of healthcare professionals (Tang et al., 
2017a), there are both personal and organisational factors which are currently acting 
as barriers to patients seeking further help for their post-stroke memory deficits. In 
this qualitative study, family caregivers and stroke-survivors were worried about a 
diagnosis of dementia; they also tended to deny or even minimise their symptoms 
and finally found obstacles with regards to the structure of primary care services 
(Tang et al., 2018c).   
 Fear of dementia is not a new concept. There have been greater efforts to 
raise public and professional awareness around dementia. This is because there can 
be some confusion particularly with regards to the early signs of dementia and 
normal ageing with poor knowledge of both risk and protective factors in the general 
public (Glynn et al., 2017). In a survey of Irish adults, substantial deficits in public 
knowledge of dementia were identified (Glynn et al., 2017). This lack of knowledge, 
particularly when it comes to the modifiable nature of the condition and the amenable 
risk factors associated with it may lead them to think not much can be done. It is 
often a lack of knowledge around the condition which may promote fear around 
dementia (Batsch and Mittelman, 2012). In a survey, conducted by Alzheimer ’s 
Disease International and published in their 2012 report, they found that 
education/awareness was a frequent response when asked what could be done to 
reduce stigma (Batsch and Mittelman, 2012). In the same survey over 75% of 
respondents with dementia felt that there are negative associations i.e. stigma 
associated with dementia (Batsch and Mittelman, 2012). Charities may have an 
annual day or week campaign where the focus is to increase awareness. For 
example the Alzheimer’s Society have a “Dementia Action Week 
(https://www.alzheimers.org.uk/get-involved/dementia-action-week)” and Alzheimer’s 
Disease International has deemed that September is World Alzheimer’s month with 
World Alzheimer’s day on the 21st September each year (https://www.alz.co.uk/world-




around dementia did lead to a significant reduction in stigma (Cheng et al., 2011). 
Even with this heightened awareness, the focus of World Alzheimer’s month (2019) 
was the “Let’s talk about dementia: End the Stigma” campaign. It was hoped that 
through talking about dementia it could break down the fear and stigma surrounding 
dementia so that individuals could be encouraged to seek help. Contributing factors 
to this stigma include lack of awareness and understanding for example around the 
aetiology of dementia (Mukadam and Livingston, 2012) as it is particularly worse in 
those with limited knowledge of the disease  as well as in the context of ethnicity and 
culture (Herrmann et al., 2018). As evidenced by the participants in this survey, 
stigmatic belief has been consistently identified to be a barrier to help-seeking for 
dementia (Werner et al., 2014, Herrmann et al., 2018). This has led to efforts to 
produce novel interventions to combat this stigma in general that can also be applied 
to stroke-survivors who are at increased risk of developing dementia. A recent 
example of this includes an online intervention program utilising educational and 
“contact” (i.e. video clips reflecting on what it is like to live and care for someone with 
dementia) approaches (Kim et al., 2019). Another example utilising an 
“intergenerational choir” compromising college students, people with Alzheimer’s 
Disease and a family member found that not only were there benefits (i.e. reduced 
social isolation) for the older choir members but the college students also displayed a 
decrease in stigma (Harris and Caporella, 2014). Although there are interventions to 
reduce stigma in dementia, it should not be forgotten that worldwide, there is also 
stigma associated with a stroke illness (Deng et al., 2019, Sarfo et al., 2017, Hare et 
al., 2006). This additional stigma may further increase the reluctance for stroke-
survivors to access help for their new post-stroke cognitive symptoms, further 
delaying earlier diagnosis of a dementia illness and access to appropriate 
interventions and support. Besides stigma, additional factors such as fragmented 
care and cognitive deficits have been found to affect recovery post-stroke (Magwood 
et al., 2019). As evidenced through both papers in this chapter, stroke survivors with 
new post-stroke memory deficits will have to overcome not only stroke-specific 
barriers but also the barriers associated with a potential dementia diagnosis i.e. the 
stigmatisation of the illness. It would be understandable therefore why perhaps a 
stroke-survivor, with preserved insight into their new deficits, would then wish to 
adapt to these deficits in order perhaps to avoid seeking further help from his or her 




 Another barrier identified by stroke-survivors and their family caregivers in this 
study was related to the organisational aspects of primary care. Participants talked 
about the importance of continuity, familiarity and also personal interaction (i.e. face 
to face contact) with regards to their issues. Given the perceived sensitive nature of 
the topic of for example a potential dementia diagnosis, it is understandable why the 
patient would want to discuss this with a familiar health professional. Familiarity and 
previous connections with the patient could also enable the healthcare professional 
to notice subtle differences in cognition, mood and behaviour. However, the majority 
of dementia diagnoses are made in secondary care by memory clinic services 
following referral by the GP. There is therefore an additional hurdle before a 
dementia diagnosis is made even if the individual is willing to attend an appointment 
to discuss this with his/her GP. National guidance stipulates that anti-dementia drugs 
should be initiated following “specialist assessment” either in clinic or in the 
community setting (National Institute for Health and Care Excellence, 2018). 
However, in recent NICE guidance, a specialist can refer to either secondary care 
medical specialists or other health professionals, including GP’s and nurse 
consultants who have the “specialist expertise in diagnosing and treating Alzheimer’s 
disease” (National Institute for Health and Care Excellence, 2018). There are 
currently new models of care integrating primary care services into the dementia 
diagnostic pathway, for example primary-care led memory clinics (Wells and Smith, 
2017). One example is the Gnosall initiative which has been ongoing since 2009 
(Greening et al., 2009). They have been able to utilise and mix the skills and 
knowledge of a consultant psychiatrist making the diagnosis, with a primary 
healthcare team (Greaves et al., 2015).  This has resulted in patients being seen 
within a month from referral, minimal use of secondary care mental health services 
with high satisfaction with the service for all those involved i.e. patients, families and 
referrers (Greaves et al., 2015, Clark et al., 2013). In the South Gloucestershire 
primary care memory service, where GPs are asked to diagnose dementia 
themselves, those interviewed felt that specialist support and expertise from 
secondary care is still needed particularly for complex cases (Dodd et al., 2016). In 
general, patients themselves found both primary and secondary care led dementia 
pathways to be acceptable (Dodd et al., 2014). A similar primary care model could be 
used with emphasis placed on those who are at heightened risk such as those with 
recent or recurrent stroke. Some form of stratification could take place within 




to dementia. Those at high risk could then access primary care models of care such 
as the examples above which would remove these apparent gaps in care.  These 
types of primary-care led memory services may be able to overcome some of these 
primary-care related organisational factors particularly in the context of stroke and 
new cognitive deficits. It would also provide further clarity to services and where both 
primary and stroke healthcare professionals can reassuringly direct at-risk patients 
to, so that stroke patients and their family aren’t left feeling unsupported.  
5.5 Chapter Summary 
 From the accounts of patients, family caregivers and healthcare professionals, 
it is clear that there are a number of barriers that need to be overcome in order for 
potential PSD patients to be identified. There is a mixture of both personal and 
organisational factors that are current barriers to help-seeking behaviour by patients 
who develop new stroke-related cognitive deficits. There are already recognised 
difficulties in the general population with regards to obtaining a dementia diagnosis in 
the first place. These difficulties are even more prominent when you also add in a 
potentially disabling stroke illness. In order to overcome these barriers, we need to 
be able to think of innovative models or approaches to correctly identify those who 






Chapter 6: Can we use risk prediction tools to identify post-stroke 
individuals at risk of dementia? 
6.1 Interventions to Reduce Risk of Further Cognitive Decline Post-Stroke  
In recognition of the increasing global burden of disease and overlap of at risk 
populations, there have been international calls for the joint prevention of stroke and 
dementia (Hachinski, 2015, Hachinski et al., 2018) including the Berlin Manifesto 
issued by the World Stroke Organisation (Hachinski et al., 2019). In theory, 90% of 
strokes could be prevented as ten potentially modifiable risk factors have been found 
to be collectively associated with around 90% of the population attributable risk for all 
strokes worldwide (O'Donnell et al., 2010, O'Donnell et al., 2016). Similarly, active 
treatment of hypertension and interventions for other risk factors such as exercise, 
reducing smoking, diabetes and obesity may have the potential to delay or even 
prevent a third of dementia cases (Livingston et al., 2017). A recent update to the 
evidence has found that the proportion of preventable or delayed dementia 
diagnoses could be as high as 40% (Livingston et al., 2020). Evidence from a 
population-based study that has shown concomitant reductions in stroke and 
dementia incidence rates over the same time period (Cerasuolo et al., 2017), 
suggesting that perhaps preventing stroke could also prevent some cases of 
dementia.  
6.2. Overview of Dementia Risk Models 
A number of dementia risk prediction models have been developed already 
(Stephan et al., 2010, Tang et al., 2015, Hou et al., 2019). A taskforce convened by 
the Alzheimer’s Society prioritised prevention of future cases of dementia through 
increasing knowledge of risk and protective factors; this includes the development of 
life course models of dementia risk (Pickett et al., 2018). The aim of dementia risk 
models is to be able to accurately predict those at the greatest risk of the disease. 
Earlier identification can then lead to earlier intervention and support. Challenges to 
this include a lack of definitive biomarkers and treatments as well as personal 
preferences and views as to whether the individual would want to know this 
information. However, there are no models currently being used clinically despite this 
explosion of dementia risk prediction model research and it is important to 




6.3. Dementia Risk Prediction Models in Stroke Populations 
Within the context of stroke, only three models have been developed to predict 
post-stroke dementia (Lin et al., 2003) and cognitive impairment (Kandiah et al., 
2016, Chander et al., 2017). The risk model developed to predict post-stroke 
dementia (n=283) at 3 months included variables such as age, occupation, number of 
attacks, left carotid vascular territory, right carotid vascular territory, admission NIH 
Stroke Scale score, admission Mini-Mental State Examination score, admission 
Function Independence Measure motor score (Lin et al., 2003). This model correctly 
classified 93.4% of patients in the development study based on these variables (Lin 
et al., 2003). Although neuroimaging variables do not add much to general population 
dementia risk models (Stephan et al., 2015), this may be different in stroke 
populations. A recent study looking at predictors of post-stroke cognitive impairment 
(PSCI) found that independent factors associated with PSCI included brain structural 
measures such as total grey matter volume, white matter hyperintensity volume and 
cerebrospinal fluid volume (Molad et al., 2019). Indeed, the two most recent risk 
scores for post-stroke cognitive impairment included neuroimaging variables at much 
shorter follow-up periods. The SIGNAL2 risk score is a seven item risk score based 
on variables include demographics (age and education) as well as neuroimaging 
variables (acute cortical infarcts, white matter hyperintensity, chronic lacunes, global 
cortical atrophy and intracranial large vessel stenosis) (Kandiah et al., 2016). This 
was similar to the CHANGE risk score which again contained demographic (age and 
education) as well as neuroimaging variables (chronic lacunes, hyperintensities in 
white matter regions, non-lacunar cortical infarct (acute) and global cortical atrophy) 
(Chander et al., 2017). Both models showed good discriminative accuracy (SIGNAL2 
AUC=0.829, CHANGE AUC=0.74 – 0.82). However, if such as models incorporating 
neuroimaging variables were to be used in clinical practice, it’s not clear how cost-
effective or how feasible it would be to obtain such neuroimaging variables in order to 
facilitate these risk prediction models.   
6.4. Limitations of Available Models at Present 
At present, no models have been recommended for use in clinical practice for 
a number of reasons but an important methodological consideration is the limited 
amount of research in external validation of these models (Tang et al., 2015, Hou et 
al., 2019). Further, models will have been developed in populations with different 




generalisability of findings challenging. External validation uses a new cohort or 
population independent of the development population in order to examine how 
reliable the model is in predicting the outcome for clinical use (Debray et al., 2015). 
Without this step, models may be recommended without the appropriate examination 
of how generalisable they are to external populations. Difficulties encountered, 
particularly if using for example electronic health records, include missing data, non-
standardised definitions of variables required or incomplete follow-up times and event 
dates (Riley et al., 2016). Despite calls for this to be done previously (Tang et al., 
2015), in the latest systematic review of dementia risk models, only a handful have 
been externally validated since (Hou et al., 2019).  
  There are emerging variables such as novel biomarkers (microRNAs 
(Shigemizu et al., 2019)) and combinations of cognitive, genetic and MRI variables 
(Payton et al., 2018), which have been shown to improve the accuracy of risk 
prediction models. In the context of stroke, the Rates, Risks and Routes to Reduce 
Vascular Dementia or R4VaD is an ongoing observational longitudinal study with the 
aim of determining the rates of cognitive impairment and dementia at least 2 years 
post-stroke with routine brain imaging and bloods taken for genetic analysis 
(http://www.isrctn.com/ISRCTN18274006). However, there has also been a lack of 
assessment in cost and feasibility of data gathering for the models to be used (Hou et 
al., 2019). Neuroimaging and genetic variables can be costly, with limited to no 
availability in primary care where they might be used. This is compared to more 
readily accessible variables such as demographic, lifestyle or health variables which 
tend to be recorded in electronic health records. Further, as evidenced by the fact 
that a GP’s clinical judgement actually holds additional value in predicting dementia 
(Pentzek et al., 2019), it should be remembered these models only serve to guide 
clinicians in clinical decision making and does not replace the clinicians themselves. 
Many of the models currently available have been developed in Caucasian 
populations (Hou et al., 2019). Racial and ethnic disparities in dementia prevalence 
are present (Chen and Zissimopoulos, 2018). It is felt that ethnicity may impact 
dementia (specifically AD) through age of onset, comorbidities, family history as well 
as genetic factors and cognitive change over time (Chen and Panegyres, 2016). In 
the context of stroke, there is some evidence that those of Black ethnicity have a 
higher risk of developing dementia following a stroke (Shiekh et al., 2020). On the 




differences in cognitive decline (Levine et al., 2015b). This has led to even more 
models specific for example in Asian (Li et al., 2018, Park et al., 2019) populations.  
Finally, given the fear and anxiety over the possibility of a future dementia 
diagnosis could generate, these risk prediction models need some qualitative 
assessment to see how appropriate and acceptable they are to use in the future. 
However, when presented with concepts such as dementia case finding and risk 
assessment, patients tend to find it difficult to grasp the key concepts (Robinson et 
al., 2018). The participants in this study did value earlier diagnosis but without any 
symptoms, the views of risk assessment for dementia varied (Robinson et al., 2018). 
Participants here expressed a preference for risk assessment to be embedded in 
routine checks for healthier lifestyles rather than specifically aimed at dementia 
(Robinson et al., 2018). There needs to be caution in terms of ensuring individuals 
understand what is involved and preferences are explored before implementing 
proactive approaches to be used in routine clinical practice (Robinson et al., 2018).  
A first step would be to see if current dementia risk prediction models actually 
validate well in stroke populations.  
6.5 PP5. Assessing the Predictive Validity of Simple Dementia Risk Models in 
Harmonised Stroke Cohorts.  
Tang EYH, Price CI, Robinson L, Exley C, Desmond DW, Kohler S, Staals J, Lam 
BYK, Wong A, Mok V, Bordet R, Bordet A-M, Dondaine T, Lo JW, Sachdev P, 










































































6.5.1 PP5 Commentary  
This is the first study to externally validate dementia risk prediction models in 
stroke populations. In order to increase the size of the population to test the models, 
multiple stroke cohorts were harmonised. The main aim was to assess whether risk 
prediction models for dementia that were developed in the general population would 
transport well to stroke populations. It was hoped that these models, which have 
been externally validated in other populations may replicate well in stroke particularly 
as the models chosen also used readily accessible variables that could be accessed 
in primary care.  
Harmonisation of multiple stroke cohorts has advantages and disadvantages. 
The obvious advantage is that through harmonisation we are able to increase our 
validation cohort and therefore incident dementia cases. The benefits of increasing 
the size of our validation sample must then also be weighed up against limitations 
including missing data, availability of model variables and broad and/or differing 
classifications of variables across cohorts. Harmonisation of multiple cohorts was 
possible through the collaboration with the Stroke and Cognition Consortium 
(STROKOG) who have been able to also harmonise data from multiple studies and 
found that there was high prevalence of post-stroke cognitive impairment in diverse 
populations (Lo et al., 2019). A similar international consortium, the Cohort Studies of 
Memory in an International Consortium (COSMIC) (Sachdev et al., 2013), has 
previously harmonised multiple international cohorts and were able to determine the 
prevalence of Mild Cognitive Impairment (Sachdev et al., 2015) and determinants of 
cognitive performance and decline across populations (Lipnicki et al., 2019). The 
same methodology could possibly be used to develop dementia risk models specific 
for stroke populations particularly if more stroke-specific variables are to be 
considered.  
 The performance of these dementia risk models in stroke populations to 
predict dementia has been found to be poor. It is likely that predictors of favourable 
or worse cognitive outcome in the context of stroke is different. In a study looking at 
those with first-ever strokes or TIA without pre-existing cognitive impairment, they 
found that lower age and lower medial temporal lobe atrophy grade on MRI at 12 
months were associated with a favourable outcome, defined as normal cognitive 
function or mild cognitive impairment after 7 years (Hagberg et al., 2019). Further, in 
a sample of stroke and TIA patients, a recent study found that 5 year risk of dementia 
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was associated with age, event severity, previous stroke, dysphasia, baseline 
cognition, low education, pre-morbid dependency, leucoaraiosis and diabetes 
(Pendlebury and Rothwell, 2019). Age and education continue to be persistent non-
modifiable with diabetes the only vascular risk factor. Given that the models tested 
contained other vascular risk factors such as smoking, alcohol and high cholesterol, it 
is perhaps not surprising that these models do not work well in stroke populations. 
This may be because the stroke illness itself already takes into account the majority 
of these vascular risk factors and the remaining variables, except perhaps age, do 
not add much more predictive ability to the model. Further, a brain imaging variable 
in the form of leucoaraiosis, was again associated with the development of dementia 
and yet none of the models tested contained neuroimaging variables. It may be that 
modifying cardiovascular factors on its own has little affect particularly in stroke 
patients where the risk is already there and in theory should be well managed to 
prevent recurrent stroke. Certainly the Prevention of Dementia by Intensive Vascular 
care (preDIVA) trial looking at the effect of a multidomain cardiovascular intervention 
did not find a reduction in the incidence of all-cause dementia over 6 years (Moll van 
Charante et al., 2016). The intervention consisted of 1) assessment of cardiovascular 
risk factors such as smoking, diet, physical activity, weight and blood pressure with 
subsequent individually tailored lifestyle advice given; 2) initiation or optimisation of 
medication for hypertension, dyslipidaemia, type 2 diabetes and antithrombotic 
medication 3) educational sessions (Moll van Charante et al., 2016). This is similar to 
findings from the Systolic Blood Pressure Intervention Trial where intensive blood 
pressure control did not result in a significant reduction in the risk of probable 
dementia, although there were fewer than expected cases of dementia (Williamson et 
al., 2019). However, unlike the FINGER trial who did find that intervention in an at-
risk group could improve or maintain cognitive functioning (Ngandu et al., 2015) the 
preDIVA study team used an unselected group of older adults and did not select 
those at increased cardiovascular risk (Moll van Charante et al., 2016). This may be 
important given that they did find that the multidomain intervention had the strongest 
effect among those with untreated hypertension (Moll van Charante et al., 2016). 
 So far, the accuracy and the validity of these models has been considered but 
we need to understand that for patients and their families in particular, an 
assessment of risk for dementia is an entirely novel approach. As assessment for a 
future possible dementia illness may be perceived to be different compared to an 
individual’s cardiovascular risk. It is therefore important to understand and discuss 
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dementia risk models with those at-risk of the condition such as a stroke population, 
so it is possible to understand the barriers and facilitators to their implementation. 
6.6 PP6. The Views of Public and Clinician Stakeholders on Risk Assessment 
Tools for Post-Stroke Dementia: A Qualitative Study 



















































































































































































































6.6.1 PP6. Commentary 
 This paper brings together the views of stroke-survivors, their family care 
givers and clinicians from the interviews that were conducted. In this study, barriers 
and facilitators were identified to risk assessment for stroke patients. All three groups 
agreed that one barrier was the perceived anxiety generated from a potential 
diagnosis of dementia. Patients and carers were also worried about how it may affect 
their recovery and clinicians were concerned about the limited interventions that were 
available even if risk assessment could identify those who need further help (Tang et 
al., 2019). The facilitators discussed included reassurance of what these symptoms 
may mean, enabling patients and carers to be prepared and for a diagnosis to be 
obtained. Primary care clinicians talked about how there was familiarity around risk 
assessment whereas secondary care clinicians discussed the need for specialist 
input. However, there was a recognition on the value of collaborative primary care 
and secondary care pathways (Tang et al., 2019).  
 Chapter 5 highlighted the fears and stigma surrounding a dementia diagnosis. 
In this chapter, patients and their caregivers also discussed how a potential diagnosis 
may then affect them particularly if they have started to resume normal daily 
activities. This highlights some additional challenges around screening and case 
finding that was discussed in Chapter 2. It has been previously discussed in Chapter 
5 about the importance of collaborative and better interface between primary care to 
look after these individuals. Here when discussing risk assessment, there was a 
similar feeling about perhaps using the expertise across the primary and secondary 
care spectrum particularly with regards to a risk assessment process.  When 
considering the use of risk assessment tools, there certainly needs to be a balance 
between the accessibility of risk model variables and also model accuracy. Variables 
which are difficult to obtain because it may only be found in specialised settings such 
as MRI may also be more costly to obtain. However, if they do indeed improve 
dementia risk models then perhaps, they do need to be incorporated in some way. 
One approach suggested by Licher et al, has been a stepwise approach with a basic 
model (age, history of stroke, subjective memory decline and need for assistance 
with finance or medication; C-statistic 0.78) being used in primary care and an 
extended model incorporating cognitive testing, brain MRI parameters and genetic 
data (C-statistic 0.86) being used in specialised settings (Licher et al., 2018a). These 
complimentary models are able to predict dementia with some degree of certainty at 
10 years follow-up, which would allow time for intervention prior to the onset of the 
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dementia syndrome (Johnson and Asthana, 2019). Interestingly in the basic model 
for the study by Licher et al, three of the four variables can be found in the Brief 
Dementia Screening Indicator (Barnes et al., 2014), which did not perform well in our 
external validation study in stroke patients. Further, as the incidence of dementia is 
nearly 50 times higher in the year after a major stroke, it may well be that in order to 
incorporate variables such as MRI predictors, we need to consider developing a 
stroke-specific dementia risk prediction model for use in secondary care settings 
rather than primary care as a) these specialised settings should have these variables 
to hand b) it minimises the delay between onset of memory or cognitive complaints 
and then access to memory services.  
6.7 Chapter Summary 
 Although there is emerging evidence in the useful application of these risk 
models in the context of trials, there are some limitations in their potential clinical use. 
Certainly, at present these tools should not be offered universally, however there will 
be people who may appreciate an earlier diagnosis or perhaps even an explanation 
of their perceived change in cognition. Further, stroke-specific models need to be 
developed if their use clinically were to be considered. The question remains as to 











Chapter 7: Gaining Consensus to Improve the Care of Stroke-
Survivors with Cognitive Deficits 
7.1 Current Clinical Services 
 The National Service Framework for Older People (2001) (Department of 
Health, 2001) and the National Stroke strategy (2007) (Department of Health, 2007b) 
both contain recommendations that all stroke-survivors and their carers should 
receive regular reviews of their health and social care needs. Structured health and 
social care review at 6 months, 12 months and then annually after a stroke is also 
recommended in the National Clinical Guidelines for Stroke (Intercollegiate Stroke 
Working Party, 2016). The review at six months following discharge from hospital is 
to ensure that stroke-survivors are supported in the community and that ongoing 
access is provided to services as needed. This includes a consideration for further 
specialists assessment if there are psychological changes (Intercollegiate Stroke 
Working Party, 2016). The Sentinel Stroke National Audit Programme (SSNAP) 
provides a national register of stroke care in England, Wales and Northern Ireland 
aiming to measure both the quality and organisation of stroke services (Sentinel 
Stroke National Audit Porgramme). As part of SSNAP, memory and cognition 
assessment are considered by recording whether patients were screened for mood, 
behaviour or cognition since discharge in clinical records.  
(https://www.strokeaudit.org/SupportFiles/Documents/Clinical-Datasets-and-Help-
Notes/SSNAP-Core-Dataset-4-0-0.aspx). The Greater Manchester Stroke 
Assessment Tool (GM-SAT) has been described as a feasible and acceptable post-
stroke assessment tool that provides a structured and systematic way to approach 
the six-month review (Rothwell et al., 2013, Bamford et al., 2013). The GM-SAT has 
also been used by the Stroke Association when they conduct their post-stroke 
reviews (https://www.stroke.org.uk/professionals/life-after-stroke-services/post-
stroke-review). The GM-SAT includes a specific question about whether the stroke-
survivor has had any difficulty with memory, concentration and attention. It has been 
updated to GMSAT2 in order to include those living in care homes so that it can 
support reviews for all stroke-survivors (https://clahrcprojects.co.uk/news/gm-sat-re-
launch).  
 A previous audit of six-month reviews found that despite these 
recommendations and a structured assessment tool, only a quarter of clinical 
commissioning groups were offering six month reviews with some services not being 
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able to provide this service to all stroke-survivors in their locality (Walker et al., 2014). 
One possible reason for this poor provision may be due to a lack of clear policy 
guidance in terms of service requirements (Walker et al., 2014). With regards to post-
stroke care, annual reviews of post-acute organisational SNNAP audit are able to 
provide an overview of where further improvements could be made to improve stroke 
clinical care. The most recent SSNAP audit annual report found that only around 
32% of patients are receiving a six-month assessment (Sentinel Stroke National 
Audit Programme, 2020). At present, between 2013 to 2019, the proportion of those 
receiving a six month review has only increased from 20% to 32% (Sentinel Stroke 
National Audit Programme, 2020). To address this, the National Stroke Programme 
aims to ensure three times as many patients receive 6-month reviews of their 
recovery and needs (Stroke Association, 2019). Despite the perceived benefits of 
such reviews, there are no apparent benefits at 12 months following a structured 
reassessment system for patient and their carers at 6 months post-stroke (Forster et 
al., 2009). This may be because the intensity of the intervention may not have been 
sufficient to affect problems 6 months after stroke-onset (Forster et al., 2009). It 
should be noted that cognition is only a small proportion of this review with many 
other areas needing to be addressed, and it cannot be assumed that more in depth 
cognitive assessment would not be beneficial. As evidenced by the findings from the 
qualitative study in chapter 5, there is often less focus on cognition during holistic 
assessment, so perhaps there needs to be more specific attention or guidance given 
to clinicians conducting the six-month review. 
 
7.2 Service User Experiences 
A previous study has reported that patients and carers have found the six-
month review to be a useful mechanism to discuss their concerns but were uncertain 
about its purpose (Abrahamson and Wilson, 2019a). It’s becoming clear, that a 
standardised structured assessment has its limits particularly when there is a lack of 
focus with regards to a patient’s concerns. There have been recommendations that 
the six month review be patient-led and for a more “targeted” approach (Abrahamson 
and Wilson, 2019b). Cognitive difficulties are a common unmet need (Chen et al., 
2019a) with as many as 9 out of 10 stroke survivors reporting impact on at least one 
cognitive function where 83% described problems with their memory (Stroke 
Association, 2018b). In chapter 6, the role of a clinically useful risk assessment 
model was discussed. A risk assessment approach could gauge individualised risk, 
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but one consideration may then need to be about what to do with the result. It was 
therefore important to bring together the findings of the previous work presented in 
this thesis to stroke clinicians to explore how we could improve the care and 
identification of those at the greatest of risk of further cognitive decline post-stroke.  
 
7.3 PP7. Care Priorities for Stroke Patients Developing Cognitive Difficulties: A 
Delphi Survey of UK Professional Views.  
Tang EYH, Robinson L, Exley C, Flynn D, Stephan BCM, Price C. (BMC Health 

































































7.3.1 PP7 Commentary 
 In this national Delphi survey of stroke healthcare professionals’ views, we 
were able to reach consensus on the majority of statements after round one, perhaps 
a reflection on the need for further emphasis by stroke clinicians on cognitive 
difficulties post-stroke. The main findings from the study for stroke-survivors with 
cognitive problems include the following: 1) Access to psychological services is 
important particularly for young stroke-survivors 2) Allied health professional follow-
up was felt to be important and should be prioritised in the community 3) Screening 
for a mood disorder is important. Across different scenarios exploring risk 
assessment, there were different views about priorities according to the information 
presented. Specifically, for those deemed to be at high risk, it was felt that direct 
access to memory clinic services would be helpful and those at lower risk more 
conservative measures needed to be adopted such as screening for a mood disorder 
and signposting individuals to further information. Interestingly throughout the 
scenarios, cognitive screening by a GP was ranked consistently as a low priority. 
Similarly, unless they were young stroke patients, cognitive screening at the six-
month review was generally not approved. This was unless a risk assessment tool 
was involved where it was then ranked in the top 4 actions overall for high and low-
risk outcomes.  
 The report by NHS Improvement on “Psychological Care after stroke” 
highlighted the need for clear pathways for referral to either neuropsychology or 
clinical psychology when assessing cognition, with a fast track route for urgent 
support if needed (Gillham and Clark, 2011). The six week and six month review 
should be used to monitor changes (Gillham and Clark, 2011). There is a lack of 
psychological services on offer to patients as evidenced from the most recent 
SSNAP report (Sentinel Stroke National Audit Programme, 2020). In 2011, the Care 
Quality Commission conducted the “Supporting Life After Stroke” review of stroke 
services (Care Quality Commission, 2011). Neuropsychology (regarding cognitive 
difficulties) and psychological therapy were amongst the lowest readily available 
forms of support reported by primary care trusts, with less than 40% of areas 
providing good access (Care Quality Commission, 2011). This gap in provision will 
unfortunately result in more people not receiving the support they need although 
more research is needed to identify an evidence-based intervention specific for 
cognitive issues post-stroke. It may also mean that as these cognitive deficits are not 
picked up initially, if they become apparent as physical recovery progresses or they 
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develop into a dementia illness, diagnosis will be delayed. It is therefore not 
surprising that clinicians in this Delphi study would strongly advocate access to 
psychological care.  
 Clinicians surveyed also valued allied health professional follow-up in the 
community. In the Care Quality Commission report, there was good availability in all if 
not most parts for services such as speech and language therapy, occupational 
therapy and general physiotherapy (Care Quality Commission, 2011). This again 
highlights that the main focus in stroke rehabilitation has been on physical recovery. 
However, participants in this study felt that more allied health professional help is 
required in the context of cognitive issues following a stroke. Although we did not 
specify which allied health professional would be most helpful, occupational 
therapists do aim to ensure maximum levels of function and independence in life 
post-stroke (Legg et al., 2006). This will of course include an assessment of cognitive 
function as cognitive impairment post-stroke can limit independence during activities 
of daily living (Zinn et al., 2004). However, a previous systematic review assessing 
the effectiveness of occupational therapy for post-stroke cognitive impairment only 
identified one trial , and advised more research was needed because the study 
population was small in this trial (Hoffmann et al., 2010). Given the current lack of 
evidence for supplementary occupational therapist intervention, it is therefore 
important to understand which allied health professional would be able to undertake 
the most effective assessment and response in the community.  
 Participants emphasised the need for mood to be screened for those with 
post-stroke cognitive difficulties. Around 31% stroke-survivors develop depression 
following a stroke (Hackett and Pickles, 2014). This is important as around half of the 
patients who have a major depressive disorder can also have generalised cognitive 
impairment (Kohler et al., 2010). In fact, cognitive impairment has been found to be a 
consistent predictor of post-stroke depression (Towfighi et al., 2017). There have 
been recommendations that cognition and mood disorders should be screened at 
different stages along the stroke assessment pathway from acute assessment to 
outpatient clinic and beyond (Quinn et al., 2018). Despite this, cognitive screening by 
GPs was not favoured by participants nor was it approved for patients presenting 
with cognitive complaints unless they were young or when a risk assessment 
procedure has been carried out. With regards to the consistent disapproval for GP’s 
to do cognitive screens, future research should examine why this might be the case 
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and what alternatives there might be to determine the role of the GP, particularly as 
stroke services end at the 6-month review. As Quinn et al have proposed, dementia 
should not be diagnosed till at least six months post-stroke (Quinn et al., 2018) and 
patients need to have a clear contact point in order for such an assessment to be 
made. This might be where risk assessment tools could prove to be useful for 
determining the direction of follow-up care. The high-risk patients could be directed to 
a specialist memory clinic and those at low risk could continue to be monitored in 
primary care. If this decision is made during the six-month review, then this would 
ensure that patients developing a future dementia illness are not left without support. 
The difficulty would be the additional work this generates for memory clinics and 
whether they have the capacity to take on this additional at-risk population.  
 
7.4 Chapter Summary 
 In this chapter some guidance has been provided for the management of 
cognitive issues after stroke from a national panel of experts. Participants have 
highlighted the need for more psychological service input which is already a 
recognised challenge for stroke services. Risk prediction tools on their own, as 
evidenced in chapter 6, can lead to concerns about the benefits of a service 
response, but participants highlighted a possible different direction for both high and 
low risk scenarios. Risk assessment tools can also emphasise to the clinician the 
need for cognitive assessment. The next step is to be able to produce a risk 
assessment tool which can accurately discriminate between high and low risk stroke 









Chapter 8. Discussion 
In this chapter I bring together the findings from the seven published papers 
presented in this thesis. A short commentary following each paper in the previous 
chapters has already been provided. For this final chapter I: 
a) Present the principal findings of my published manuscripts in relation to the 
objectives set out in chapter 1; 
b) Discuss the overall strengths and limitations of my findings; 
c) Supplement the commentaries in the previous chapters by presenting these 
findings in relation to other similar work being conducted in this field; 
d) Highlight the clinical implications of the principal findings of my thesis; and, 
e) Discuss the future work needed along the clinical care spectrum of post-stroke 
dementia based on the work presented in this thesis.  
8.1 Principal findings 
The research findings have highlighted some key limitations in the current 
clinical care pathway in supporting stroke-survivors who may be at risk of a future 
dementia illness. The potential use of risk assessment tools to assist in the 
identification of individuals at risk of post-stroke dementia has also been explored.  
The key findings in relation to the objectives are as follows: 
 
Objective i): To describe the impact of cognitive difficulties post-stroke over 
time 
 
Through a systematic review of the available literature (paper 1; (Tang et al., 2018a) 
patterns in post-stroke cognition were described by investigating changes in cognitive 
test scores over time. While most stroke survivors showed general cognitive decline, 
this was not found universally. Cognitive function post stroke could stabilise or even 
recover, and this was dependant on both the follow-up time and the cognitive domain 
examined. There were also variables associated with impairment which included age, 
ethnicity, premorbid cognitive performance, depression, stroke location and a history 
of stroke. 
 
Objective ii): To describe the current care provision from the perspectives of 
patients, carers and key professionals 
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The findings from papers 2 – 4 ((Tang et al., 2017a, Tang et al., 2018c, Tang et al., 
2020a) highlight the lived experience of stroke-survivors with memory difficulties as 
well as the experiences of their families. They also provide clinician perspectives on 
the care received by stroke-survivors with cognitive difficulties in general. During 
these interviews, stroke-survivors and their family carers discussed the physical and 
emotional impact that the stroke illness and the memory difficulties have had on their 
daily lives. They reported adaptations they made in order to continue to try and 
function in the community. However, they also expressed a number of difficulties in 
accessing the care they need due to both personal (fear of dementia and 
minimisation of symptoms) and organisational (barriers found in primary care 
services) factors. These service gaps were also acknowledged by primary and 
secondary care clinicians. Organisational (lack of clarity in service pathways and less 
focus on cognition in stroke care) and clinician-related (difficulties in discussing 
cognition and assumptions made in clinical care) factors were found to contribute to 
gaps in care for these patients. 
 
Objective iii): To explore the use of risk prediction tools to identify those most 
at risk 
 
Dementia risk prediction tools have primarily been developed and externally 
validated in the general population rather than in disease specific groups (e.g. people 
with stroke or cardiovascular disease). Paper 5 (Tang et al., 2020b) examines the 
performance of dementia risk prediction models developed for use in the whole 
population when applied to people with a history of stroke. However, the current 
dementia risk models do not perform well in stroke cohorts. Therefore, if this 
approach is to be used then stroke-specific models would need to be developed and 
then externally validated in stroke populations to ensure their accuracy, 
generalisability and transportability. As part of the qualitative interviews, clinicians, 
patients and their family carers were asked their thoughts about incorporating risk 
prediction models into the care of stroke-survivors (Tang et al., 2019). The opinions 
were mixed. From their accounts, although there might be benefits to this approach, 
it should not be applied universally due to concerns about the potential diagnosis of 
dementia, lack of intervention after assessment and how it may affect recovery. To 
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be told you are at risk of dementia having recovered well from your stroke could be 
concerning for some.  
 
Objective iv): To seek the views of professionals on the key findings from the 
previous objectives with a view to suggesting improvements in future care. 
 
An exploratory national electronic Delphi exercise was conducted focussing on 
priority actions at the six-month clinical review and how a dementia risk prediction 
tool could be incorporated into services. The main input that stroke clinicians wanted 
was the assistance of other healthcare professionals such as psychological services 
and enhanced allied health professional follow-up. Dementia risk prediction tools 
could be used to identify those at high risk who could possibly be redirected to 
memory clinics. 
 
8.2 Strengths and limitations of the studies overall 
The body of work presented in this thesis provides a comprehensive overview 
of the current care of stroke-survivors with memory difficulties and how interventions, 
such as risk prediction models, could be used in the clinical pathway to improve the 
identification and care of patients at highest risk of post-stroke dementia. The work 
involved a wide range of stakeholders such as primary and secondary clinicians 
(including allied health professionals) both locally and nationally (for secondary care 
professionals), and most importantly the views of patients and their families. There 
was also the opportunity to collaborate and learn from international colleagues to 
maximise the potential of multiple stroke datasets through harmonisation.  
The external validation of dementia risk models in stroke cohorts is the first 
examination of harmonised datasets being used to determine whether existing 
dementia risk models validate well in people with a history of stroke. A previous 
paper has also highlighted the current methodological weaknesses in dementia risk 
prediction literature including the over-reliance on one data source and a lack of 
validation (Goerdten et al., 2019). The study externally validating these models in 
stroke cohorts adds further evidence in this field but also takes into account these 
weaknesses.  
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Throughout the research process patients and the public assisted in the 
development of the research materials used and provided feedback on the findings 
and dissemination strategies. Sufficient time was given, at least annually to listen to 
their feedback to improve the overall research programme; this was often the 
highlight of the PhD process. Arguably, the biggest strength has been to bring to the 
fore the “hidden” issues of memory and cognitive difficulties in stroke survivors to a 
wide ranging clinical and non-clinical audience. Often, research and clinical services 
focus on the physical recovery from stroke. This work highlights aspects of the 
recovery process that clinicians may not always identify themselves, despite the fact 
that they acknowledge its importance in the patient journey.  
 There are some limitations in the presented studies. For the systematic 
review, the focus was on the change and trajectory of cognitive test scores. This was 
because of existing systematic reviews on dementia outcome in relation to stroke 
(Kuzma et al., 2018, Savva and Stephan, 2010). However, cognitive test score 
deficits may not necessarily reflect the individual’s ability to function or indeed their 
own perceived deficits. It is recognised that stroke-survivors could perform well on 
cognitive testing but then struggle to function and perform activities of daily living and 
vice versa. Therefore, although this body of work has increased our understanding 
on how patient’s perform in terms of cognitive testing over time across cognitive 
domains, it does not provide evidence of how these cognitive deficits subsequently 
affect functioning. There also needs to be some consideration given to how 
perceptual and physical impairments may interact with cognitive deficits. Although 
this was in part supposed to be answered in the qualitative interviews, I also 
recognise that cognitive testing was not done in recruiting stroke-survivors to the 
interviews.  
With regard to the qualitative studies, the inclusion criteria required only 
subjective memory concerns which meant in terms of the spectrum of cognitive 
deficits this somewhat limited in my sample. Patients may have had difficulties with 
attention, information processing or executive functioning but this was not clear from 
the participants recruited as there was no formal cognitive assessment. Additionally, 
it was not clear whether patients were referring to ongoing cognitive difficulties since 
their stroke, which they became more aware of since returning home, or whether this 
had commenced after their discharge from hospital. Further, as these were memory 
concerns reported by the patient, they may have had pre-morbid memory difficulties 
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which became more obvious following the stroke and were therefore not directly due 
to the stroke itself. Further, memory concerns are generally one of the most common 
cognitive deficits experienced and reported by stroke-survivors (Stroke Association, 
2018b). In order to determine the effect of objective cognitive deficits on daily 
functioning, patients would need to be recruited following objective cognitive testing. 
This could be for example with a stroke specific cognitive test such as the Oxford 
Cognitive Screen which is freely available and takes into account stroke deficits such 
as aphasia and neglect (Demeyere et al., 2015). As evidenced by the systematic 
review, follow-up time is important with cognitive decline generally found with longer 
follow-up times. It would therefore be helpful to follow-up patients and their families 
over a longer period than the first 12 months post-stroke. A further limitation of the 
qualitative studies was that the patients recruited were mobile and well enough to 
attend the six-month clinic review. There will be those with more severe major stroke 
and not able to attend their review who may be more at-risk of dementia and may 
encounter even more significant daily difficulties who were not included in this study.  
Although it was possible to harmonise a number of stroke datasets to 
externally validate the existing dementia risk models, this process has its limitations. 
The first involves the different definitions of the risk variables for example measures 
of depressive symptoms, alcohol consumption and education, across the different 
datasets. When utilising different datasets from varying geographical locations 
internationally this was to be expected. The second was the choice of dementia risk 
models chosen to be externally validated. For disease-specific models, disease-
specific variables have been found to perform well in that population for example in 
diabetes specific dementia models (Exalto et al., 2013). However, there has only 
been one stroke-specific dementia model published (Lin et al., 2003). Further the 
stroke-specific variables include neuroimaging which may have been missing or been 
reported differently across cohorts, making harmonisation even more difficult. 
Accurate models where there were available data to harmonise across the different 
cohorts were chosen. As such, there may be other untested dementia risk models 
that work better in stroke populations. The likelihood of this is probably low as the 
variables found in the tested dementia risk assessment models tended to be vascular 
in origin such as blood pressure or cholesterol. An individual who has had a stroke 
illness would tend to score high on these variables anyway and so additional stroke-
specific variables may be needed to provide additional accuracy to these traditionally 
used risk variables. Finally, although the size of the population was increased via 
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data harmonisation, the total samples that were harmonised were still relatively small 
when compared to some of the existing literature in external validation in dementia 
risk prediction (Stephan et al., 2020, Licher et al., 2018b, Exalto et al., 2013). 
However, by their very nature stroke cohorts tend to be smaller samples but it is 
recognised that more datasets might have provided better power for analysis of co-
variates, but it was at the discretion of the individual studies as to whether they were 
permitted and willing to share their data.  
The national electronic Delphi survey incorporated the views of stroke 
clinicians only. Primary care professionals are also involved in the care of stroke-
survivors at risk of dementia. However, a definite clinical focus point in the service 
pathway was needed so this could be enhanced and improved upon particularly as 
the six-month reviews are routinely conducted due to national recommendations. 
This is why the study focussed on the six-month clinical review which is generally 
conducted in stroke outpatient services. There are some limitations to this approach. 
First, the majority of clinical care following a stroke is found in the community, which 
may or not be part of hospital with only limited contact with specialist stroke services 
following discharge. This means that if a long-term intervention was to be trialled it is 
likely that this will be most appropriately placed in the community. In terms of 
identifying those suspected of having a dementia diagnosis, GPs perform brief 
cognitive test scores alongside careful history and examination and appropriate 
investigations (Robinson et al., 2015). However, from this Delphi survey, having GPs 
perform cognitive testing post-discharge was generally the lowest ranked option 
across the scenarios. This presumably placing the onus on stroke services to carry 
out this assessment. This may reflect the traditional lack of primary care involvement 
in post-stroke care for example, in the latest periodic national audit of stroke six-
month reviews, only 0.1% of six-month reviews were conducted by GPs, with only 
around 7 in 10 eligible stroke patients receiving mood, behaviour and cognition 
screening (Sentinel Stroke National Audit Programme, 2019b). However, only around 
a third of applicable stroke survivors receive a six-month review in current clinical 
care (Sentinel Stroke National Audit Programme, 2019c), which means there is a 
substantial number of stroke survivors who do not get follow-up long term care 
through stroke services. This is despite the fact that around three quarters of all 
stroke survivors are eligible for follow-up (Sentinel Stroke National Audit Programme, 
2019c). This may or may not reflect the fact that many stroke patients have their high 
care needs met in 24-hour care, which means that they have sufficient monitoring in 
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the community. This highlights the importance of community follow-up which is 
through the GP. Second, although there was good geographical coverage of 
clinicians from the invitations sent out, the spectrum of those conducting six-month 
reviews was restricted to mainly physicians and nurses. In some areas, allied health 
professionals including staff employed by parties such as the Stroke Association 
conduct some of these six-month reviews and therefore it would have been useful to 
obtain more of their views. Finally, there may be other options besides the ones 
presented to participants to improve the care of those at-risk of dementia. However, 
the options were informed through discussion amongst the research team and also 
the previous work presented in this thesis.  
8.3 Interpretation in relation to other studies 
 In the previous chapters, a brief commentary after each paper has been 
provided to place each study in the context of existing literature. This section will look 
to build upon this existing commentary and bring together the findings from the entire 
thesis in relation to the overall picture presented in the current literature.  
 Similar to paper 1 (Tang et al., 2018a), previous studies have looked at 
cognitive changes over time. This has been in relation to frequency of cognitive 
impairment (Sexton et al., 2019) or dementia (Kuzma et al., 2018) over time. These 
studies have confirmed the increased risk of cognitive impairment and dementia 
following a stroke, which is also what paper 1 concluded through cognitive testing. A 
more recent systematic scoping review by Saa and colleagues (Saa et al., 2019) has 
built on the systematic review  (Tang et al., 2018a). Here, the authors looked at 
studies evaluating cognition longitudinally and identified the instruments and domains 
they used (Saa et al., 2019). Fourteen articles were included in my study, which 
looked at the frequency of for example those who decline cognitively, those who 
recover or stabilise. The study by Saa et all included 257 studies, which looked at the 
descriptive characteristics of included studies in detail for example the instruments 
used, domains tested and the use of functional cognitive assessments (Saa et al., 
2019). The systematic review did not look at a specific group of stroke-survivors. This 
is in contrast to my own systematic review, which ensured that the population tested 
in my systematic review was dementia free at baseline. Further, the review looked at 
those who were older i.e. ³50 years old; this was to provide a broader picture of 
those at risk of developing dementia from cognitive impairment particularly as age is 
a strong risk factor for dementia. Although the focus of Saa’s review was on the 
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characteristics of the measures of cognitive over time, it was complimentary to the 
systematic review submitted in this thesis as it highlights the broad range of multi and 
domain specific tests currently used for both intervention trials and observational 
studies in the current literature. As per the study authors’ conclusions, there also 
needs to be better organisation and standardisation in the field of cognitive testing to 
improve our understanding of cognitive trajectory post-stroke (Saa et al., 2019). 
However, it was then important to understand the actual impact on patients in order 
to know what interventions they may require which was the aim of the qualitative 
study. 
The qualitative study focussed on subjective memory difficulties and concerns 
rather than any objective measures. It is known that new memory impairments are 
commonly found post-stroke and can occur even amongst patients with excellent 
clinical recovery (Jokinen et al., 2015). Further, older (i.e. aged 65 years and over) 
chronic stroke patients have been found to show significantly more impairment in 
cognitive domains such as executive functioning and verbal memory when compared 
to younger stroke patients (Nakling et al., 2017). Unfortunately, currently identified 
tools to measure subjective memory impairment in the literature do not provide an 
accurate reflection of memory impairments post-stroke (Salis et al., 2019). However, 
subjective memory impairment or complaints are known to be associated with future 
dementia (Brigola et al., 2015, Jessen et al., 2010, Schmand et al., 1996, Jonker et 
al., 2000) . Midlife forgetfulness also appears to be an indicator of increased 
dementia risk in old age (Ishtiak-Ahmed et al., 2019). It is known that self-reported 
concerns about worsening memory in patients with mild cognitive impairment is a 
predictor of future dementia (Wolfsgruber et al., 2014). It is therefore reasonable to 
clarify with the patient if they have experienced any memory concerns following their 
stroke in order to consider whether any further assessment is required for a future 
dementia illness through cognitive testing or even onward referral to memory clinics 
or further additional review in the community.  
There have been numerous qualitative studies exploring the impact of stroke 
on stroke-survivors and caregivers as well as the organisation of services (McKevitt 
et al., 2004). The patient and family caregiver interviews were specifically targeted at 
those experiencing subjective memory complaints (Tang et al., 2018c) and the 
impact this had (Tang et al., 2020a). The study here adds to the qualitative literature 
for this specific at-risk stroke subgroup of stroke patients also reporting memory 
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concerns. The barriers identified in primary care however are not specific to this 
stroke subgroup. A recent systematic review of qualitative studies of stroke-survivors 
and their caregivers’ experiences of primary care found that in general stroke 
survivors feel abandoned and marginalised by services (Pindus et al., 2018). It was 
noted that only a minority of studies included in this review included data on specific 
long term impairments such as cognitive impairment (Pindus et al., 2018). Some of 
the recommendations to address these negative perceptions included information 
provision and improving the continuity of care between specialist and generalist 
services (Pindus et al., 2018). These two facilitators of information provision and 
better integrated care were also found when healthcare professionals were 
interviewed in my study (Tang et al., 2017a). The focus of this thesis was not to 
develop interventions to alleviate the impact of subclinical cognitive difficulties. The 
purpose of this body of work was to show why patients at risk of post-stroke 
dementia and their families require more assessment and clinical intervention than 
they can access in standard services. This is particularly relevant because a 
proportion of these individuals will go on to develop a dementia illness. It is therefore 
important to know if we are able to identify these individuals earlier and whether 
stroke patients would value such an intervention. Risk assessment tools are one 
objective way to achieve this, but their cost effectiveness and ethical concerns 
around their use still need to be determined. Importantly, they require external 
validation to assess how transferable and generalisable they are in a population 
separate to the development cohort before they can be used. 
Studies focussing on external validation of dementia risk models have been 
limited (Stephan et al., 2016). There have been previous papers externally validating 
dementia risk models (Exalto et al., 2014, Licher et al., 2018b, Stephan et al., 2020). 
A recent study by Stephan et al (Stephan et al., 2020), applied similar methods to the 
external validation study presented here and looked at the performance of some of 
the same models used (Tang et al., 2020b) namely the Cardiovascular Risk Factors, 
Aging and Dementia risk score, the Australian National University Alzheimer’s 
Disease Risk index and the Brief Dementia Screening Indicator (Stephan et al., 
2020). They tested the models in low-income and middle-income countries, as the 
dementia prediction models have generally been developed and tested in high 
income countries (Stephan et al., 2020). The authors found a mixed picture in terms 
of external validity when assessing the accuracies of these models in external 
populations, although the Australian National University Alzheimer’s Disease Risk 
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index and the Brief Dementia Screening Indicator models did perform similarly to the 
development cohorts (Stephan et al., 2020). However, this was not tested in disease-
specific populations as in the study presented in this thesis. Further, when Licher and 
colleagues externally validated the same three models in an elderly community-
dwelling population, they found that all models were similar in discrimination when 
compared to prediction based on age alone (Licher et al., 2018b). These studies 
highlight the need for new and updated models to be developed as well as the need 
to look at disease-specific risk prediction models.  
There has also been some risk prediction models developed in stroke 
populations to predict dementia (Lin et al., 2003) and post-stroke cognitive 
impairment (Chander et al., 2017, Kandiah et al., 2016, Ding et al., 2019). However, 
to our knowledge this is the first study to examine the performance of general 
population-based dementia risk prediction models in stroke populations. Multiple 
cohorts were also harmonised to increase the sizes of the samples used, which is a 
similar approach used by previous studies (Lipnicki et al., 2019, Lo et al., 2019). This 
is because when compared to general population cohorts, stroke cohorts in general 
are small hospital-based samples as evidenced by the numbers used to develop the 
stroke models (range n = 179 (Ding et al., 2019) – 283 (Lin et al., 2003)). The 
majority of stroke models are to predict post-stroke cognitive impairment whereas the 
focus of investigation is a dementia outcome. Further it was not possible to validate 
these stroke models due to limited and differing available variables across the 
cohorts I had access to.  However, the study (Tang et al., 2020b) has further 
emphasised that stroke-specific dementia risk models are needed. Although the 
focus of the external validation study was on risk models that could be used in 
primary care, this limits the types of variables that can be incorporated into such 
models. Indeed, if blood based (or cerebrospinal fluid based) biomarkers and 
neuroimaging variables are to be incorporated into stroke-specific models this would 
mean that risk prediction models would have to be used in specialist settings to 
obtain the necessary variables. One area that has received considerable interest has 
been the use of neuroimaging variables, which were incorporated into both models 
developed for predicting post-stroke cognitive impairment (Chander et al., 2017, 
Kandiah et al., 2016).  
In a systematic review of studies, global brain and medial temporal lobe 
atrophy have been found to be the most consistent predictors of post-stroke cognitive 
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impairment (Casolla et al., 2019). Predictors of a favourable cognitive outcome (i.e. 
normal cognitive function or mild cognitive impairment) post stroke in a study that 
looked at 7 years follow-up for those after first-ever stroke or TIA included lower 
medial temporal lobe atrophy grade on MRI (Hagberg et al., 2019). Other potential 
imaging variables that have been associated with the development of dementia in 
stroke patients include imaging markers of severe small vessel disease (i.e. presence 
of ³3 lacunes and confluent white matter changes) (Mok et al., 2016) and 
leucoaraiosis (Pendlebury and Rothwell, 2019). Stroke subtype may also be 
important as a higher number of cerebral microbleeds, higher cortical atrophy score 
and disseminated superficial siderosis have been found to be risk factors for new-
onset dementia in those who have a stroke due to intracerebral haemorrhages 
(Moulin et al., 2016). In terms of blood biomarkers, there is currently no convincing 
biomarker (including APO e4, cholesterol, C-reactive protein, glycated haemoglobin 
A1c and homocysteine) which can accurately diagnose or predict post-stroke 
cognitive impairment (Casolla et al., 2019). There have been some studies for 
example using plasma D-amino acid oxidase (Chen et al., 2019b), which have been 
associated with PSD that need further exploration but at present there are no 
effective blood biomarkers for PSD (Mijajlovic et al., 2017). Based on current data, it 
is possible that neuroimaging variables could assist in the development of more 
accurate stroke-specific dementia risk models, which could be of use in specialist 
settings. An initial simpler, stroke-specific community screen could also be 
considered prior to specialist setting involvement to further stratify these individuals.   
The qualitative study also provides important insights about the views of 
stakeholders, including stroke survivors, about dementia risk assessment (Tang et 
al., 2019). Previous studies have sought the views of clinicians on the use of risk 
prediction models in general (Muller-Riemenschneider et al., 2010, Sarazin et al., 
2013) and also in disease-specific settings (Liew et al., 2013). In dementia, a survey 
of primary care professionals found that participants agreed that risk prediction 
models could be helpful in practice (Tang et al., 2018b). When members of the public 
were asked for their views on risk assessment in dementia, there was a preference 
for this to be embedded within routine health checks. However, participants also felt it 
important as they considered this a complex area comprising a range of approaches 
including case finding and genetic screening (Robinson et al., 2018). This qualitative 
study for stroke patients therefore adds to the existing literature as it specifically 
addresses the question as to whether risk assessment tools for dementia would be 
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suitable for a stroke population. In my study, with risk assessment in general, 
understanding individual preferences is key. Similarly participants in the study by 
Robinson et al also discussed the negative psychological consequences of proactive 
approaches for example not wanting to know because of their personal experiences 
of seeing others with dementia or worrying about future dementia when they are 
asymptomatic (Robinson et al., 2018). With such concerns, it was important to know 
how to incorporate these findings into clinical practice. One way to possibly achieve 
this was to seek expert consensus opinion on how to improve the six-month review, 
which is dictated by national policy and expert guidance. This was the stroke six-
month review. The findings of the previous studies were brought together in a Delphi 
survey and the opinions of experts in the UK were sought. 
The Delphi survey specifically focused on management of cognitive problems 
at the six-month clinic review. Previous studies around the six-month clinic review 
concentrated on the assessment tools used (Patchwood et al., 2020) and the 
purpose and outcomes of the review (Abrahamson and Wilson, 2019a). A recent 
study looked at whether unmet needs post-stroke were addressed by the six-month 
review but the focus was on physical needs, secondary prevention and self-
management (Abrahamson and Wilson, 2019b). There has been little focus on the 
cognitive aspects of care at this clinical review. This study has therefore been able to 
provide evidence as to what could be valuable from a cognitive perspective and 
could be incorporated into routine clinical practice. For example, it was clear from the 
participants in this study that GPs performing cognitive assessments post-discharge 
was not favoured (Tang et al., 2020c). Further, cognitive assessments were 
approved particularly in the young stroke-survivor with cognitive problems and when 
risk assessment for dementia was incorporated into clinical care at the six-month 
review (Tang et al., 2020c). Unfortunately, in the UK, the percentage of stroke-
survivors receiving six-month reviews is still suboptimal with only 32% of eligible 
patients receiving a review according to the latest annual report from SSNAP 
(Sentinel Stroke National Audit Programme, 2020). Even if patients are able to be 
reviewed at 6 months, the requirements from SSNAP simply ask whether the patient 
was screened for mood, behaviour or cognition since discharge using a validated tool 
and whether support was offered 
(https://www.strokeaudit.org/SupportFiles/Documents/Clinical-Datasets-and-Help-
Notes/SSNAP-Core-Dataset-4-0-0.aspx). Although there is no recommended 
cognitive screen for stroke patients dictated by SSNAP or national guidance, there is 
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a requirement to assess how many patients have received screening. However, the 
reporting of SSNAP groups mood, behaviour and cognition together as a single 
category so it is not entirely clear what proportion of patients have had a cognitive or 
mood screen or indeed both. In the latest available SSNAP periodic report (July to 
September 2019), just over a third (36%) of stroke-survivors who were eligible 
managed to receive a six-month review and around 1 in 4 required additional support 
(Sentinel Stroke National Audit Programme, 2019b). Of these, around 1 in 5 patients 
did not receive a screen for mood, behaviour or cognition (Sentinel Stroke National 
Audit Programme, 2019b). Although the total number screened are an improvement 
from previous annual figures, as around than 1 in 4 stroke-survivors did not get 
screened for mood, behaviour or cognition in the 2013–2014 annual report, the 
proportion of stroke-survivors not receiving a screen has remained stagnant since 
2016-2017 (Sentinel Stroke National Audit Programme, 2019a). However, the case 
for cognitive screening at the 6-month review was felt to be important in those who 
were younger and also when risk dementia assessment tools were involved (Tang et 
al., 2020c). To achieve routine cognitive assessment it may well be that several 
changes could be suggested to the six-month review: a) for cognition screening to be 
made into a separate category on SSNAP reporting; b) a risk assessment tool to be 
considered in order to prompt clinicians to conduct a cognitive screen; and, c) a 
universally accepted stroke-specific cognitive screen to be agreed upon for example 
the OCS. There also needs to be some uniformity not just in terms of the screening 
tools used, but also how cognitive assessment is incorporated into these clinical 
reviews, so the clinician knows how to conduct and respond to them. This is because 
according to the latest periodic SSNAP report, there is a great variety in the 
professional backgrounds of individuals conducting the reviews (Sentinel Stroke 
National Audit Programme, 2019b) for example, secondary care clinicians (8.2%); 
stroke coordinators (33%); therapists (13.4%); district/community nurses (9.8%) and 
voluntary service employees (11.5%) (Sentinel Stroke National Audit Programme, 
2019b). Importantly, almost 1 in 5 (19.5%) of these reviews are conducted by 
telephone, with some even being conducted via post (0.3%) or online (0.1%) 
(Sentinel Stroke National Audit Programme, 2019b); similar approaches would make 
cognitive testing particularly challenging.   
8.4 Clinical Implications 
 Findings from my research (Tang et al., 2017a) support recommendations 
from experts in clinical guidance (Intercollegiate Stroke Working Party, 2016) and 
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findings from qualitative studies, which were synthesised (Pindus et al., 2018). There 
are consistent reports that improvements in care can be achieved through 
collaborations between primary care teams with hospital/specialist care, particularly 
in terms of follow-up and annual review (Intercollegiate Stroke Working Party, 2016). 
The Intercollegiate Stroke Working Party recommends that: 
“People with stroke, including those living in a care home, should be offered a 
structured health and social care review at six months and 1 year after the stroke, 
and then annually. The review should consider whether further interventions are 
needed, and the person should be referred for further specialist assessment if a) new 
problems are present;  b) the person’s physical or psychological condition, or social 
environment has changed.” (Intercollegiate Stroke Working Party, 2016). 
The aim of these reviews is to identify any ongoing needs that require additional 
intervention and referral for specialist assessment (Intercollegiate Stroke Working 
Party, 2016). 
After the 6-month review, patients are invited to an annual review by their GP. 
As part of the Quality and Outcomes Framework, GPs are required to keep a register 
of stroke or TIA patients. They are also required to reduce the occurrence of 
recurrent stroke by addressing vascular risk factors, for example ensuring good blood 
pressure control, prescribing and compliance of antiplatelet or anti-coagulant 
medication as appropriate and offering support to stop smoking (NHS Digital, 2019). 
There is no requirement (or incentive) for GPs to address cognitive assessment post-
stroke since the dementia enhanced service was removed (National Health Service 
(England), 2015). This service had previously incentivised GPs to undertake case 
finding for those at-risk of dementia which included patients aged 60 or over who had 
a previous stroke (National Health Service (England), 2015). From the findings of this 









Figure 1. Proposed Integrated Pathway 
 
 
In secondary care, it is important that services recognise the importance of 
picking up cognitive concerns in a timely fashion. The potential to develop dementia 
following a stroke is not a new finding and despite this, assessments to identify and 
intervene in cognitive deficits remains under resourced and under developed as 
evidenced by for example the limited amount of psychological services available 
when compared to physical rehabilitation (Care Quality Commission, 2011). It may be 
increasingly difficult to increase psychological resources so that there is uniformity in 
care, which means stroke patients require other objective assessments so we can 
risk-stratify and stream individuals to the appropriate services. The following changes 
could be implemented to facilitate this: 
 
8.4.1 Recommendations for Clinical Practice (1): SSNAP Dataset 
Paper 1 of this thesis adds to the literature in terms of the frequency and 
burden of cognitive difficulties experienced by stroke-survivors (Tang et al., 2018a). 
In order to fully comprehend the burden of cognitive problems post-stroke when 
auditing, one recommendation would to be to ensure that the SSNAP dataset has a 
separate section for cognition i.e. question 8.2 “was the patient screened for 
behaviour or cognition using a validated tool” could be changed so that cognition is 
an independent outcome. Although mood and cognitive problems can co-exist, mood 
issues such as anxiety or depression tend to be more obvious to the clinician 
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conducting an assessment than subtle cognitive difficulties. In 2018, the Stroke 
Association undertook a large survey on the lived experience of strokes. In their 
report, although around three quarters of stroke survivors experience at least one 
mental health problem (e.g. anxiety, depression or even suicidal thoughts); however, 
9 out of 10 stroke survivors experience at least one cognitive effect with memory 
problems affecting 83% of stroke patients, which is higher than the highest physical 
impact (i.e. on balance at 82%) (Stroke Association, 2018b). It is clear from the 
survey by the Stroke Association that there is a significant burden of both cognitive 
and mood problems and this needs to be picked up separately so appropriate 
services can be tailored to the individual needs of the patient.  
 
8.4.2 Recommendations for Clinical Practice (2): Patient-Led Post-Stroke 
Reviews 
There is consistent evidence and argument for patient led reviews so that they 
are targeted to meet patient needs (Abrahamson and Wilson, 2019b, McKevitt et al., 
2011) which may be different to clinician priorities. Paper 2 in this PhD has 
highlighted the impact on patients (Tang et al., 2020a), which may not be so obvious 
to healthcare professionals because patients have managed to adapt. McKevitt and 
colleagues also specifically commented on the need to develop primary care-based 
strategies to assess and meet the long term unmet needs encountered by patients 
(McKevitt et al., 2011). Andrew and colleagues echoed this recommendation and 
also highlighted support for caregivers in the community (Andrew et al., 2015). To 
further support families affected by stroke, there needs to partnerships between them 
and service providers via a network which includes health and social care as well as 
voluntary organisations (Perry and Middleton, 2011). Long term stroke care should 
be consistent, targeted and more bespoke to address ongoing or new needs but also 
enable gaps in care to be highlighted (Forster et al., 2015). This will require regular 
and multiple reviews so there needs to be a connection and pathway from specialist 
services into primary care.  
8.4.3 Recommendations for Clinical Practice (3): Proposed Changes to the Six-
month Review  
 Papers 2 – 4 have highlighted current gaps and challenges throughout the 
care pathway (Tang et al., 2017a, Tang et al., 2018c, Tang et al., 2020a). Even 
healthcare professionals themselves have admitted to making assumptions in who 
manages what aspect of care (Tang et al., 2017a) highlighting a lack of clearly 
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defined roles and responsibilities in a clinical pathway, which may hinder integrated 
working. There needs to be a clear direction of care to ensure those at-risk of 
dementia are not missed.  
 As highlighted by the Delphi study in paper 7 (Tang et al., 2020c), there are 
certain assessments that could be included at the six-month review which could help 
streamline those into the appropriate levels of intervention and care. One further 
recommendation is the need for uniformity in the screening assessments performed 
for both mood and cognition. Although there are those that are still not receiving any 
form of cognitive screen at a time when it is most appropriate, the SSNAP audit 
reports that 93% of patients receive mood and cognition screening within 6 weeks of 
admission, although only 5% of stroke patients in hospital are found to be applicable 
for psychology review (Sentinel Stroke National Audit Programme, 2020). One 
approach would be for patients who display some cognitive deficit on the initial 
screen to be highlighted at the six-month review for further, more formal and detailed 
cognitive assessment. Paper 5 has highlighted that current risk prediction models do 
not work well in stroke populations, which means stroke-specific models need to be 
developed before implementing them in clinical practice (Tang et al., 2020b). Further 
in paper 6, again there needs to be care in whom we offer this assessment to as 
there may be concerns about how it will affect their recovery as well as the 
underlying fear of a potential dementia diagnosis (Tang et al., 2019). But if patients 
would like to undergo this assessment, then as paper 7 highlights, there are benefits 
to this approach (Tang et al., 2020c):   
Firstly, there is seemingly a connection between carrying out the risk 
assessment and then also clinicians feeling it is important to carry out a cognitive 
assessment. An example of such a cognitive screen would be the OCS which has 
been adapted across different international populations (Garcia-Manzanares et al., 
2020, Huygelier et al., 2019, Robotham et al., 2020, Shendyapina et al., 2019, 
Valera-Gran et al., 2019) and has been found to be more sensitive than the MMSE in 
detecting cognitive impairment in stroke patients (Mancuso et al., 2018). It also 
detects cognitive deficits not picked up by another common dementia cognitive 
screening tool, the MoCA (Demeyere et al., 2016). This will then enable a baseline 
assessment to be carried out and if local psychological services are available they 
could also be referred for targeted interventions. Further it has been shown that 
cognitive impairment (no dementia) at 3 months post-stroke is a significant predictor 
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of long term incidence of dementia in stroke patients (Allan et al., 2011). This 
highlights that there needs to be some sort of mechanism or pathway for clinicians to 
risk assess those who have some cognitive impairment shortly after their stroke so 
that a dementia diagnosis is not missed. 
The second benefit of a dementia risk assessment tool is the ability to stratify 
the management of patients with new memory/cognitive deficits. In paper 7, 
participants felt that if they were found to be high risk then they should be referred to 
the memory clinic (Tang et al., 2020c). This would enable them to be assessed for a 
diagnosis of post-stroke dementia and then provided with the necessary intervention 
and support. This is particularly important as the incidence of dementia is nearly 50 
times higher in the year after a major stroke compared to the general population 
(Pendlebury and Rothwell, 2019). Meaning that if they were found to be at high risk 
of dementia with a validated tool at the 6-month review, then they could be referred 
on in a timely fashion without delay. This could be done directly from stroke services 
so that at-risk patients are not missed upon discharge. 
8.4.4. Recommendations for Clinical Practice (4) Better Integration of Primary 
and Secondary Care Services 
 To ensure the flow of care continues and does not stop abruptly following 
specialist service discharge, specialist pathways need to be better integrated across 
the primary-secondary care interface. Patients and their families have already 
expressed concerns and barriers to seeking help in primary care in paper 4 (Tang et 
al., 2018c). Stronger links between primary and secondary care were also identified 
as a facilitator to improved care in this field by clinicians in paper 3 (Tang et al., 
2017a). This could be facilitated through standardised communication with the GP, 
for example by providing them with detailed information of the assessments carried 
out in stroke services especially regarding cognition. As highlighted by participants in 
the Delphi study, the key for both high and low risk groups then needs to be ensuring 
secondary prevention is adequate to prevent recurrent stroke which increases an 
individual’s risk of future dementia (Pendlebury and Rothwell, 2009). The difference 
between the two groups would be where they would be referred to in the clinical 
pathway depending on the level of risk.  
It is then important that those deemed to be at lower risk are not neglected. By 
virtue of their stroke, they are at higher risk than the general population to develop 
dementia anyway (Kuzma et al., 2018). This means that primary care clinicians need 
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to have access to information and resources which would aid them to assist stroke 
patients and their families to identify any day-to-day deficits which might indicate the 
need for memory clinic referral in the future. This can be reviewed regularly at their 
annual reviews and should be in addition to the current measures carried out which 
at present simply addresses secondary prevention.   
8.5 Implications for Research 
8.5.1 Dementia Risk Prediction Models for Stroke Populations 
 There is an ever-increasing number of risk prediction models for dementia 
(Tang et al., 2015, Hou et al., 2019) and yet none are currently in clinical use. There 
clearly needs to be a balance between accuracy of the models as well as the 
number, complexity and cost of the variables needed to obtain an accurate risk 
assessment (Warren-Gash, 2019). Dementia risk models have traditionally used 
regression modelling but there is a growing body of work that uses machine learning 
algorithms to develop dementia risk models (Goerdten et al., 2019). Machine learning 
uses computational methods in order to find complex patterns in data which are then 
used to make clinical predictions. They could for example be used to identify 
variables to be used in a dementia risk model or be used to distinguish normal 
cognition versus dementia on brain imaging. However, machine learning methods to 
predict dementia risk from neuroimaging are not yet ready to be used because it 
does not reliably differentiate between clinically relevant disease categories 
(Pellegrini et al., 2018). The models tend to do well in differentiating healthy controls 
from Alzheimer’s Disease but less well when mild cognitive impairment categories 
are involved and when it has to differentiate between mild cognitive impairment and 
AD (Pellegrini et al., 2018). Given the frequency of cognitive impairment in stroke, 
this is a significant barrier to the implementation of such models into clinical practice. 
There also tends to be an overreliance on one data source and this can limit 
generalisability (Goerdten et al., 2019). It may well be that the focus of future stroke-
specific dementia models looks to incorporate known predictors which are universally 
available across specialist settings such as neuroimaging markers as discussed 
above. This will require more interdisciplinary working, collaborations across cohorts 
and clearer and standardised definitions of variables to be effective. Ideally, these 
models will still contain some modifiable risk variables so that an individual can 
potentially reduce their risk. These modifiable risk factors could be targeted by 
intervention trials to, more likely, delay the onset of cognitive decline and dementia, 
or improve quality of life rather than reduce the frequency of dementia.  
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8.5.2 Development of Primary Care Roles in Stroke 
 To date, stroke care has mainly been found in hospital settings with primary 
care responsible for longer term secondary prevention. However, this ignores the fact 
that primary care could play a greater role in ensuring that patients receive better 
cognitive support and assessment. But this requires standardised communication 
from stroke services as well as the provision of resources to enable the GP to 
support the stroke patient and their family. Given the lack of emphasis placed on 
cognitive care post-stroke, the first step would be to assess whether GPs and the 
clinical team in the community such as practice and district nurses, who may be the 
ones carrying out chronic care reviews, are aware of the link between stroke and 
dementia and the risk involved. There may be a professional knowledge gap which 
needs to be addressed before such services can be offered to support these 
patients. Further, if stroke-specific cognitive screening tools such as the OCS are to 
be used in primary care teams to detect those who may be at risk of an underlying 
dementia diagnosis in the long-term then again it needs to be assessed how feasible 
and acceptable such a screen would be and how it compares to shorter cognitive 
screens that GPs are more familiar with.  
8.5.3 Multimodal Interventions to Reduce Future Risk of Dementia in Stroke 
 One criticism of risk assessing individuals for dementia, particularly post-
stroke as some of our participants said in our qualitative study, is the lack of 
interventions following assessment (Tang et al., 2019). Previous trials have been 
mixed when it comes to intensive intervention and subsequent cognitive outcome. 
Some examples include the “Prevention of Decline in Cognition after Stroke Trial” 
(n=83), which found that intensive BP and lipid lowering did not alter cognition 
following recent stroke (Bath et al., 2017). Similarly, intensive BP treatment alone in 
first-ever stroke patients did not result in reduction in MCI or dementia diagnoses 
after 1 year (Ihle-Hansen et al., 2015). When patients (n=195) were allocated to 
either vascular risk factor intervention (information provision, optimised medical 
treatment to treat risk factors such as BP, cholesterol, homocysteine and BMI to 
target, tailored advice regarding risk factor management and treatment plan sent to 
the GP) or usual care, again, there was no demonstrable effect on cognition at 12-
months follow-up (Ihle-Hansen et al., 2014). The Austrian Polyintervention Study to 
Prevent Cognitive Decline after Ischaemic Stroke (n=101 randomised into 
intervention) assessed whether an intensive multimodal intervention (adequate BP, 
lipid and glycaemic control, healthy diet, exercise and cognitive training) over a 
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longer period of 24 months could prevent cognitive decline after stroke (Matz et al., 
2015). Again, this sample did not demonstrate any significant benefit despite a longer 
follow-up duration (Matz et al., 2015). In an earlier trial (the Perindopril Protection 
Against Recurrent Stroke Study), with a larger sample (n=6105) and longer mean 
follow-up time of 3.9 years, active treatment of blood pressure did reduce the risk of 
cognitive decline but this was more pronounced when associated with recurrent 
stroke (Tzourio et al., 2003). There are ongoing trials such as the AFIVASC 
(“physical activity in vascular cognitive impairment”) group who are looking at 
whether physical activity alone can affect cognitive status in patients with vascular 
cognitive impairment or who have had previous stroke or TIA (Verdelho et al., 2019). 
Results from another trial looking at vascular risk factor management (BP, lipids, 
blood glucose and atrial fibrillation) and cognitive outcome are awaited (Myint et al., 
2017). With regards to intervention, pharmacological treatment is also being trialled. 
Following the findings of the LACunar Intervention-1 trial (Blair et al., 2019), the 
results of the LACunar intervention-2 trial are currently awaited (Wardlaw et al., 
2020). Here, the study team are assessing the efficacy of cilostazol versus isosorbide 
mononitrate or both with cognition as a secondary outcome in the hope of proceeding 
to a phase 3 trial (Wardlaw et al., 2020).  
The lack of positive findings on cognition in stroke could be due to risk 
stratification as well as smaller sample sizes and duration of intervention. The Finnish 
Geriatric Intervention Study to Prevent Cognitive Impairment and Disability is a well-
known randomised controlled trial which did find that a multidomain intervention 
consisting of diet, exercise, cognitive training and vascular risk monitoring could 
improve or maintain cognitive functioning (Ngandu et al., 2015). Here the sample size 
was larger (n=2654), the follow-up duration was 2 years and importantly they used 
the raised CAIDE score as an inclusion criteria with the mean dementia risk score of 
8.3 in those enrolled into the trial (Ngandu et al., 2014). A similar approach could be 
used in stroke trials once a stroke specific dementia risk score is established. 
8.6 Conclusion 
 The incidence of post-stroke dementia will only increase due to longer survival 
following a stroke and successful primary (and secondary) prevention. Increasing 
numbers of people living with dementia will lead to significant health, social and 
societal costs. Stroke care has traditionally focussed heavily on acute care and 
physical rehabilitation but there is consistent evidence for further resources and 
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research into the assessment and management of the cognitive aspects also 
particularly if we are to reduce the risk of future post-stroke dementia cases. This 
body of work has highlighted the challenges faced by stroke-survivors with 
cognitive/memory deficits. Yet, there is the potential for primary care and specialist 
stroke services to work closer together to reduce these gaps in care; gaps which may 
lead to missed opportunities to identify those at the greatest risk of post-stroke 
dementia. A clearer clinical pathway is needed that has been highlighted in this 
thesis from the evidence generated. There are still areas that need further work such 
as stroke-specific risk prediction, more personalised care and targeted interventions. 
It is hoped that policy makers, clinicians and other stakeholders are able to continue 
to highlight and make changes not only in clinical services but also across the 

















Personal reflections on the research 
This PhD took the best part of six years, with many challenges presented and 
overcome along the way. As a clinician I have always been aware the benefit of 
being a clinical academic when it comes to generating research ideas, involving 
patients and translating my findings into clinical practice. One inherent weakness that 
I have always felt is that we are in danger of neglecting other aspects required to be 
a confident independent academic clinical researcher, namely methodological 
expertise. I therefore made it a priority in the six years to take up the opportunities to 
attend courses, educational events, speak to experts such as my supervisors 
regularly and then apply this learning to my own research.  
I have also learnt about the balance needed as a clinical academic. During my 
PhD I went from being a GP trainee, to a GP partner at a practice and then changing 
roles to be a salaried GP. At the time, I recognised my own limitations and 
understood the need to find the right balance of clinical and academic work in order 
to make both succeed. Although I have continued to take on additional leadership 
roles, this has been complimentary rather than additive. Now at the end of the PhD I 
do believe I have found an equilibrium to enable me to realise the potential of my 
portfolio career as an academic GP.  
An unexpected problem was the emergence of the COVID-19 pandemic. 
Thankfully by then the data had been collected and I was at the stage of writing up 
my thesis. But managing clinical work, work-life balance and also motivating myself 
to write proved to be challenging. I took the opportunity to immerse myself in the 
literature and saw the potential of what I was writing in influencing patient care which 
provided the final motivation required to complete this body of work.  
I hope as I take the next steps in my academic career, I can continue to build 







Here I present my positionality with respect to my own academic training, 
clinical and personal experience and their relationship to the field of study.  
I have always seen myself as someone who likes to question and then 
formulating a plan to challenge the routine. I also like visible and quantifiable results 
that validate my questions. This way of thinking has dictated much of my career so 
far. I graduated from the University of Edinburgh with a Bachelor of Science in 
Medical Sciences (Neurosciences), Bachelor of Medicine and Bachelor of Surgery 
and a Master of Science. I completed an Academic Foundation Programme and then 
the NIHR Academic Clinical Fellowship prior to obtaining this NIHR Doctoral 
Research Fellowship. I had some grounding in basic clinical research methods 
through participating in research projects in for example the field of dementia and risk 
prediction leading up to the application for PhD funding as well as obtaining a 
Postgraduate Diploma in Clinical Research (Ageing) at Newcastle University. 
I am a pragmatist at heart as my success or failure has always been 
determined by the practical application of my research and how to reach the end 
result in a timely fashion. This has softened slightly as I’ve embraced the world of 
qualitative research and allowed the participants (rather than seeing them as data 
points) to speak for themselves. The opportunity to work with a variety of individuals 
from many backgrounds nationally and internationally was always constructive to my 
development, even when at the time I may have perceived some experiences 
negatively, although this was rare. The way I interpret both qualitative and 
quantitative data is very much how I see them answering the clinical research 
question I first posed in chapter 1. Being a pragmatist can sometimes mean I miss 
the richness of the data and findings presented before me as I am so focussed on 
how to get to the end goal. But the experience of qualitative research, experience of 
conducting my own research and mentoring I believe has helped soften this stance.  
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